Introduction {#s1}
============

Maintenance and repair of many tissues depend on reserve populations of tissue-specific stem cells. In the unperturbed state, these reserve cells are maintained at a defined pool size. Upon tissue damage, they expand to give rise to progenitors that can differentiate for efficient and timely tissue restoration as well as self-renew to re-establish the stem cell pool. With age, tissue function and regenerative capacity decline due to alterations in stem cell intrinsic function, microenvironment (niche), and systemic cues. Collectively, these changes lead to a decline in the number of functional stem cells ([@bib40]). The skeletal muscle system provides an experimental paradigm for understanding stem cell-based tissue regeneration. Because of the essentiality of skeletal muscles for mobility, metabolic homeostasis, and thermogenesis, the clinical relevance of resident muscle stem cells cannot be over-stated.

Skeletal muscle tissue can mount effective tissue restoration even after up to 50 weekly myotoxin-induced injuries in the mouse ([@bib31]). The muscle stem cells driving this remarkable lifelong regenerative response are satellite cells (SCs), which were initially discovered by Alexander Mauro in Xenopus ([@bib32]). SCs comprise a small population (5 to 7% of all muscle nuclei) of undifferentiated and quiescent mono-nucleated cells that reside between the basal lamina and the surface of skeletal muscle cells; a microenvironment referred to as their niche ([@bib7]; [@bib32]). SCs express the transcription factor Pax7 ([@bib49]). Lineage-tracing experiments unequivocally demonstrate that Pax7-expressing (Pax7^+^) SCs are of somitic origin ([@bib28]), and they are the major contributing source of myonuclei in both postnatal development and injury-induced regeneration ([@bib27]). Ablation of the Pax7^+^ cell population in adult mice establishes that they are essential for muscle regeneration ([@bib29]; [@bib33]; [@bib39]; [@bib45]). Pax7^+^ SCs first appear under the basal lamina at late stages of fetal myogenesis (day 15.5 of gestation in the mouse) ([@bib18]; [@bib43]; [@bib46]). After birth, they remain highly active to supply myonuclei for muscle growth but gradually cease to differentiate by 3--4 weeks ([@bib27]; [@bib60]). Therefore, SCs appear to be set-aside as a quiescent pool of stem cells during this time frame for muscle homeostasis and regeneration throughout lifetime.

Tremendous insights into the molecular regulation of muscle stem cells during adult regeneration and aging have been gained in recent years ([@bib6]; [@bib11]). The primary foci of those studies are regulators for SC proliferation, differentiation, and self-renewal during adult and aged muscle homeostasis and following injury. Information derived from these studies helps formulate strategies towards restoring a functionally competent SC pool to combat muscle aging and muscular dystrophies. By contrast, a significant gap exists in our current knowledge pertaining to the regulation of SCs shortly after birth when they provide myonuclei to drive tissue growth and transition into quiescence, i.e. their initial establishment. In particular, how the initial SC population is proportionally scaled with respect to the muscle size during the postnatal period is entirely unknown. In adult homeostasis, SC numbers per muscle fiber in the mouse ([@bib9]) or per defined myofiber length in human ([@bib3]) reveal very minimal inter-fiber variation. Teleologically, SC number to muscle size scaling would be most relevant to the replicative potential of SCs per given muscle tissue volume in regeneration. It seems reasonable to presume that the physiological SC/muscle ratio is developmentally set at a maximum in a given muscle group for effective regeneration later on in life. To what extent this ratio can be altered without changing muscle size or impacting regenerative potential remains unclear.

To date, loss of function studies have helped identify many necessary components for the initial fate specification and later maintenance of SCs. As such, changes in SC number in these animal models are not directly relevant to their initial scaling during the critical early postnatal period. By contrast, a 'gain-of-function' mouse model with super-numeral SCs is much desired, as its molecular dissection would much more likely enable the discovery of the molecular mechanism(s) sufficiently altering the initial SC pool size. Moreover, a robust SC hyperplasia mouse model could allow addressing the relevant clinical question of whether bestowing a tissue with extra stem cells would be of benefit or of detriment to the regenerative process of skeletal muscle and in other organismal systems. Yet, currently it is unknown whether the SC pool can be increased in the absence of overall muscle tissue hypertrophy.

Here, we report a murine SC hyperplasia model and investigate the effects on regenerative myogenesis. We had generated transgenic mice that express hemagglutin-tagged (HA)-TEAD1 driven by a 6.5 Kb muscle creatine kinase (MCK) control region ([@bib53]). TEAD1 belongs to the TEA domain transcription factor family, which serves important functional roles in multiple embryonic contexts by activating gene expression when bound to the Hippo signaling pathway effectors Yap or Taz ([@bib63]). Muscle-intrinsic changes effected by TEAD1 overexpression include a prominent transition toward a slow muscle contractile phenotype ([@bib53]). Here, we provide comprehensive analyses of the SC compartment and make the discovery of a robust, up to 6-fold increase of quiescent SCs in TEAD1-Tg mice. As a functional consequence, TEAD1-Tg muscle regenerates at a faster rate post-injury likely owing to their increased SC number as well as the increased proliferation rates observed when the myofiber-associated SCs are activated. Remarkably, in the *mdx* mouse model for Duchenne muscular dystrophy, skeletal muscle pathology is significantly ameliorated by TEAD1-overexpression, which is likely contributed in part by an increase in *utrophin* expression. Lastly, we provide evidence implicating TEAD1-Tg skeletal muscle fibers in the regulation of mouse SC number. This work implicates a role for TEAD1-induced, myofiber-derived signaling that can scale the initial SC pool size during the perinatal period. Additionally, TEAD1 overexpression appears to alter myofiber stability in the context of dystrophic disease. Further study of this mouse model will be invaluable in elucidation of physiological pathways controlling stem cell numbers, and may prove to be an entry point to modulating SC number in clinical settings.

Results {#s2}
=======

TEAD1-Tg mice have normal skeletal muscle size and number, but have SC hyperplasia {#s2-1}
----------------------------------------------------------------------------------

A remarkable feature of skeletal muscle is its ability to adapt to changing physiologic demands via reversible modulation of tissue size and of fiber-type composition, to accommodate differential force exertion or contractile usage patterns, respectively. To this end, we previously identified a regulatory role for Tead1 in the induction of slow muscle gene expression: skeletal muscle of TEAD1-Tg mice features a transition to the slow muscle contractile phenotype ([@bib53]; [@bib57]). To further confirm this transition, we employed immunofluorescence (IF) analysis to tibialis anterior (TA) muscle cross-sections from adult TEAD1-Tg and wild type (Wt) sibling mice using antibodies against fiber-type specific myosins ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Fast glycolytic myofibers express IIX myosin and make up approximately half of all TA fibers of Wt mice ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). By contrast, this fiber type is absent in TEAD1-Tg TA muscle ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}; quantification in [Figure 1I](#fig1){ref-type="fig"}). Reciprocal analysis using an antibody detecting any myosin but the IIX type confirmed the complete loss of this fiber type as all TA muscle fibers stained positive in TEAD1-Tg samples ([Figure 1---figure supplement 1C--D](#fig1s1){ref-type="fig"}; quantification in [Figure 1I](#fig1){ref-type="fig"}). While the low percentage of slow twitch (I myosin^+^) fibers is not affected, a more than 2-fold increase in IIa myosin^+^ fibers suggests that the fast glycolytic fibers are replaced in large part by fast oxidative fibers in TEAD1-Tg TA muscles ([Figure 1---figure supplement 1E--H](#fig1s1){ref-type="fig"}; quantification in [Figure 1I](#fig1){ref-type="fig"}). Whether additional tissue alterations accompany this TEAD1-induced change in fiber-type composition is unknown. For further characterization, we decided to evaluate muscle fiber number (hyperplasia) and size (hypertrophy) in TEAD1-Tg mice.10.7554/eLife.15461.003Figure 1.Skeletal muscle is histologically indistinguishable between Wt and TEAD1-Tg mice.(**A--P**) H and E (**A**--**B**, **E**--**F**, **I**--**J**, **M**--**N**) and Sirius Red (**C**--**D**, **G**--**H**, **K**--**L**, **O**--**P**) stains of TA (**A**--**D**), EDL (**E**--**H**), Plantaris (**I**--**L**), and Soleus (**M**--**P**) from Wt (**A**, **C**, **E**, **G**, **I**, **K**, **M**, **O**) and TEAD1-Tg mice (**B**, **D**, **F**, **H**, **J**, **L**, **N**, **P**). Insets are magnified images of the representative areas within the tissue. (**Q**--**S**) EDL fiber number (**Q**), fiber area (**R**), and fiber diameter (**S**) are quantified for both genotypes (n \> 3 adult mice for all measurements).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.003](10.7554/eLife.15461.003)10.7554/eLife.15461.004Figure 1---figure supplement 1.Ratios of type II fibers are changed in TEAD-Tg muscle.Wt (**A**, **C**, **E**, **G**) and TEAD1-Tg (**B**, **D**, **F**, **H**) TA muscles were queried for percentages of type IIX fibers (**A**, **B**), fibers that were not IIX (**C**, **D**), type IIa fibers (**E**, **F**), and type I fibers (**G**, **H**). The TA muscle was chosen for analysis because it is comprised of all muscle fiber types. The results were then quantified (**I**). n \> 3 adult mice for all measurements, p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.004](10.7554/eLife.15461.004)

We investigated the size of skeletal muscle of multiple hind limb muscle groups from TEAD1-Tg mice by weight and by histological staining to determine muscle fiber size and number. Four muscle groups were chosen based on their fiber-type compositions as follows: primarily fast-twitch glycolytic fibers (EDL and plantaris), slow-twitch oxidative fibers (soleus), and mixed fast- and slow-fiber types (TA) ([Figure 1](#fig1){ref-type="fig"}). Histological staining by haematoxylin and eosin (H and E), as well as, by Sirius Red of the chosen muscle groups from 3-months old TEAD1-Tg and Wt littermates did not reveal histopathology as myofiber nuclei were peripherally located, and interstitial spacing between individual fibers was normal with no excess collagen or mononucleated cells ([Figure 1A--P](#fig1){ref-type="fig"}). TEAD1-Tg mice also did not display muscle hypertrophy, as weights of all analyzed hind limb muscles were unchanged (Table 4). Because its fibers extend the entire length of the muscle, the EDL muscle facilitates accurate determination of myofib er number and size in cross sections. No differences were detected in myofiber number ([Figure 1Q](#fig1){ref-type="fig"}), or in myofiber size by cross-sectional area ([Figure 1R](#fig1){ref-type="fig"}) and fiber diameter ([Figure 1S](#fig1){ref-type="fig"}) between TEAD1-Tg and Wt samples. All together, we conclude that forced expression of TEAD1 does not induce any overt pathological (i.e. fibrosis) or size (i.e. hypertrophy or hyperplasia) alterations of skeletal muscle.

Reports of a higher density of SCs in slow-twitch compared to fast-twitch muscles ([@bib15]; [@bib47]) prompted us to investigate the SC compartment in TEAD1-Tg muscle, which has an increase in slow muscle gene expression ([@bib53]). We determined SC number by assessing Pax7^+^ cells on TA muscle sections by IF staining ([Figure 2A,B^i^](#fig2){ref-type="fig"}; quantification in [Figure 2I](#fig2){ref-type="fig"}). A striking 5-fold increase in Pax7^+^ cells in TEAD1-Tg was found as compared to Wt TA muscle ([Figure 2I](#fig2){ref-type="fig"}). This increase is of much greater magnitude than expected from the \~2-fold difference in SC number between slow- and fast-twitch muscles ([@bib15]; [@bib47]). The increase in SC number was consistent between 3 independent TEAD1-Tg mouse lines (L12, L4, L14) excluding the possibility of transgene integration sites accounting for the observed increase in SCs ([Figure 2I](#fig2){ref-type="fig"}). For the rest of this study, we utilized line L12 exclusively for consistency.10.7554/eLife.15461.005Figure 2.TEAD1-Tg hind limb features SC hyperplasia.(**A**--**H^i^**) Pax7 IF in hind limb muscle groups: TA (**A**--**A^i^**, **B**--**B^i^**), Plantaris (**C**--**C^i^**, **D**--**D^i^**), Soleus (**E**--**E^i^**, **F**--**F^i^**), and EDL (**G**--**G^i^**, **H**--**H^i^**). Wt (**A**--**A^i^**, **C**--**C^i^**, **E**--**E^i^**, **G**--**G^i^**) and TEAD1-Tg muscles (**B**--**B^i^**, **D**--**D^i^**, **F**--**Fi**, **H**--**H^i^**) are represented. **A^i^**--**H^i^** are zoomed images of areas represented by the white boxes in **A**--**H**, arrows indicate Pax7 (green) positive nuclei (blue). (**I**--**K**) Quantification of SC hyperplasia (fold increase above Wt) in TA sections from three independent TEAD1 transgenic lines with different transgene insertion sites (**I**). Quantification of TA sections from Wt and TEAD1-Tg line L12 for fold increase of myonuclei per fiber, SC per fiber, and SC per myonuclei (**J**). Quantification of plantaris, soleus, and EDL muscle group sections for fold increase in SC number in TEAD1-Tg line L12 compared to WT (K). n \> 3 adult mice for all measurements, p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.005](10.7554/eLife.15461.005)

The absence of myofiber hyperplasia and/or hypertrophy ([Figure 1](#fig1){ref-type="fig"}) argues for a specific SC hyperplasia in TEAD1-Tg muscle. To confirm this, we quantified myofiber nuclei in TA muscles, which revealed no differences in the myonuclei to myofiber ratio, yet the SC to myonuclei ratio is increased 5-fold when comparing TEAD1-Tg and Wt samples, thus establishing a selective effect in SC hyperplasia ([Figure 2J](#fig2){ref-type="fig"}). We also detected significant increases in SCs among the groups of muscle of TEAD1-Tg mice, including \~4.5-fold increase in the plantaris, \~6-fold increase in the soleus, and \~2.5-fold increase in the EDL ([Figure 2C--H^i^](#fig2){ref-type="fig"}; quantification in [Figure 2K](#fig2){ref-type="fig"}). The SC hyperplasia of the predominantly slow-twitch soleus is particularly noteworthy as it argues against the increase in SCs being a simple consequence of myofiber conversion to the slow phenotype ([@bib53]). Collectively, these findings rule out skeletal muscle hypertrophy and hyperplasia, and demonstrate specific SC hyperplasia in TEAD1-Tg fast- and slow-twitch skeletal muscles of the lower hind limb.

SC hyperplasia is established during early postnatal development {#s2-2}
----------------------------------------------------------------

During muscle development, SCs gradually become quiescent by 3--4 weeks after birth ([@bib27]; [@bib60]). Intriguingly, peak HA-TEAD1 expression is detected prior to this time, at around postnatal day 14 (PN 14d) ([@bib53]). Therefore, we next examined whether TEAD1-Tg muscles show SC hyperplasia during this early postnatal time period. SCs were quantified in hind limb muscles of TEAD1-Tg and Wt sibling mice at designated postnatal time points (PN 10d, PN 12d, PN 14d and PN 20d), as was done for adult muscles at three months ([Figure 2](#fig2){ref-type="fig"}, Materials and methods). To monitor SC proliferation during the postnatal period, we applied the thymidine analogue EdU. At PN 10d and PN 12d, we did not detect differences in the numbers of sublaminal Pax7^+^ cells or in the percentages of EdU^+^/Pax7^+^ cells between TEAD1-Tg and Wt sibling TA muscles ([Figure 3A,B^iii^](#fig3){ref-type="fig"}; quantification in [Figure 3E,G](#fig3){ref-type="fig"}). At PN 14d, TEAD1-Tg TA muscles had begun accumulating an \~1.5-fold greater number of Pax7^+^ cells when compared to Wt TA muscles ([Figure 3E,F](#fig3){ref-type="fig"}). This difference became greater at PN 20d when TA muscles boasted a \>3-fold increase in SCs in TEAD1-Tg versus Wt mice ([Figure 3C,D^iii^](#fig3){ref-type="fig"}; quantification in [Figure 3E-F](#fig3){ref-type="fig"}). Quantification of the percentage of sublaminal Pax7^+^/EdU^+^ cells at PN 20d revealed a significant 2-fold increase in the percentage of proliferative SCs in TEAD1-Tg compared to Wt TA muscles ([Figure 3G](#fig3){ref-type="fig"}). Conceivably, SCs could be protected from cell death in TEAD1-Tg muscle, which could contribute to the greater number of SCs. To assay for SC apoptosis, we performed TUNEL labeling coupled with anti-Pax7 IF on TA muscle sections from TEAD1-Tg and Wt siblings at PN 14d when initial SC increases are detected ([Figure 3H,I](#fig3){ref-type="fig"}). A single instance of co-labeling was detected in the TEAD1-Tg sections (0.15%) while none were observed in the Wt sections ([Figure 3J](#fig3){ref-type="fig"}) suggesting TEAD1-Tg SC protection from apoptosis does not drive the SC hyperplasia. Together, these data indicate that TEAD1-Tg muscle accumulates super-numeral SCs beginning at \~2 weeks after birth via extending the proliferation period. Such super-numeral SCs appear to be excluded from fusion with the myofiber (no increase in the myonuclei/fiber ratio), providing the basis for the specific increase of SCs over myonuclei number.10.7554/eLife.15461.006Figure 3.SC hyperplasia arises during perinatal stages in TEAD1-Tg mice.(**A**--**D^iii^**) Wt (**A**--**A^iii^**, **C**--**C^iii^**) and TEAD1-Tg (**B**--**B^iii^**, **D**--**D^iii^**) SC numbers and proliferation were assessed. Postnatal day 12 (PN 12d, **A**--**B^iii^**) and day 20 (PN 20d, **C**--**D^iii^**) are represented in IF images. Pax7 (green) alone is shown in **A**, **B**, **C**, and **D**, and combined with DAPI (blue) and laminin (red) in the merged images **A^i^**, **B^i^**, **C^i^**, **D^i^**. EdU (red) alone is represented in **A^ii^**, **B^ii^**, **C^ii^**, **D^ii^** and combined with Pax7 (green) in merged images **A^iii^**, **B^iii^**, **C^iii^**, **D^iii^**, arrows indicate nuclei labeled with both EdU and Pax7 while arrowheads are Pax7 positive nuclei that show no EdU label. (**E**--**G**) Numbers of SCs normalized to total myofibers per image is quantified for PN 10d, 12d, 14d, and 20d Wt or TEAD1-Tg TA sections (**E**). Fold increase in SC numbers in TEAD1-Tg TA sections compared to Wt was quantified for PN 10d, 12d, 14d, and 20d (**F**). Fold increase in percent EdU positive SCs in TEAD1-Tg TA sections compared to Wt was quantified for PN 12d and 20d (**G**). (**H**--**J**) Apoptosis rates of SCs were assessed for PN 14d. Representative images for Wt (**H**) and TEAD1-Tg muscle (**I**) show Pax7 (green) and TUNEL (red) stained nuclei (blue). Percent of SCs that were TUNEL positive or negative was quantified (**J**). n \> 3 mice for all measurements, p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.006](10.7554/eLife.15461.006)

Super-numeral SCs have normal niche interactions {#s2-3}
------------------------------------------------

During adult homeostasis, SCs localize to the myofiber sublaminal space, are highly polarized, and maintain a quiescent state, all of which is characterized by typical molecular marker expression and a non-proliferative state. To determine if super-numeral SCs of TEAD1-Tg mice have acquired the quiescent muscle stem cell state, we performed extensive marker and proliferation analyses in adult (3-months old) mice. First, we determined proper niche localization of SCs using anti-Pax7 and anti-laminin dual-IF staining ([Figure 4A,B](#fig4){ref-type="fig"}). All SCs of TEAD1-Tg muscle localized to the sublaminal space ([Figure 4G](#fig4){ref-type="fig"}). Next, we analyzed SC polarity using β1-Integrin as a basal marker and M-Cadherin as an apical marker ([Figure 4C--F](#fig4){ref-type="fig"}). Similar to controls, ≥80% of SCs displayed proper polarity ([Figure 4H](#fig4){ref-type="fig"}). Calcitonin receptor (CTR) is specifically expressed by quiescent SCs and important for maintenance of quiescence ([@bib13]; [@bib62]). Like Wt SCs, SCs from TEAD1-Tg mice express CTR ([Figure 4I--J^i^](#fig4){ref-type="fig"}; quantification in [Figure 4KJ](#fig4){ref-type="fig"}) and also the general stem cell marker, CD34 ([Figure 4K](#fig4){ref-type="fig"}). These data suggest that super-numeral adult SCs of TEAD1-Tg mice maintain proper cell polarity, niche interaction, as well as the quiescent state. To probe the quiescent state more rigorously, we conducted long-term proliferation assays via administering BrdU in the drinking water for a month and assaying for BrdU^+^ nuclei in the sublaminal space ([Figure 4L--M](#fig4){ref-type="fig"}). No differences were found in proliferation between SCs of TEAD1-Tg and those of Wt muscles ([Figure 4N--O](#fig4){ref-type="fig"}). All together, we conclude that super-numeral SCs of TEAD1-Tg muscle acquire and maintain proper niche occupation and cell polarity, as well as, the quiescent state typical of adult muscle stem cells.10.7554/eLife.15461.007Figure 4.SC localization, marker expression, and long-term proliferation are no different in TEAD1-Tg compared to Wt mice.(**A--H**) Localization of SC (Pax7, green) within the muscle fiber basal lamina (laminin, red) shown by IF of adult Wt (**A**) and TEAD1-Tg (**B**) TA sections and quantified for TEAD1-Tg TA sections (**G**). Polarized Integrin-β1 expression (Integrin, green) in SCs (Pax7, red) was assessed on TEAD1-Tg and Wt isolated EDL fibers (myofiber, mf) and found to be basally localized in all instances where the position of the SC on the fiber allowed for assessment (**C**,**D**). M-Cadherin (Mcad, green) polarization in SCs (Pax7, nuclei shown in red) was assessed in TA sections for apical localization (**E**,**F**), which is quantified in **H**. Non-polarized Mcad in Wt and TEAD1-Tg samples is likely due to imperfect SC orientation within the section. **I--K**) Assessment of quiescent marker (calcitonin receptor, CTR) expression in SCs (Pax7, **I^i^** and **J^i^**) on Wt (**I**) and TEAD1-Tg (**J**) isolated EDL fibers are represented by IF and quantified in **K** along with the general stem cell marker, CD34. **L--N**) Following a month-long BrdU treatment, Wt (**L**) and TEAD1-Tg (**M**) adult TA sections were assessed for long-term proliferation. Since myonuclei are non-proliferative and SC nuclei present the only other sublaminal nuclear species, this assay cumulatively captures any SC proliferation over the one-month long period. Very low numbers of BrdU nuclei were detected in both sublaminal and interstitial compartments of TA muscles from TEAD1-Tg and Wt mice. BrdU (green) labeled nuclei (blue) within the basal lamina (red) of the myofiber were quantified (**N**) and normalized to SC number (**O**). For **G**, **H**, and K n \> 50 cells, while for **N**, 3 mice were quantified for each genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.15461.007](10.7554/eLife.15461.007)

Skeletal muscle regeneration is accelerated in TEAD1-Tg mice {#s2-4}
------------------------------------------------------------

Since we found SCs of TEAD1-Tg skeletal muscle to have a normal quiescent phenotype ([Figure 4](#fig4){ref-type="fig"}), we next asked whether they retain the functional capacity to regenerate tissue after injury. To determine this, the TA muscles of adult (2--3 months old) TEAD1-Tg and Wt littermates were injured by intra-muscular injection of cardiotoxin (CTX; see Materials and methods). Histological analyses of muscle regenerates were performed 3, 7, and 14 days post injury (dpi, [Figure 5A--F^i^](#fig5){ref-type="fig"}). Remarkably, while not detectable in Wt samples, very small regenerative myotubes could be detected histologically at 3 dpi in TEAD1-Tg regenerates ([Figure 5A--B^i^](#fig5){ref-type="fig"}), indicating that the regeneration process is accelerated in muscle with super-numeral SCs. To confirm this, we applied IF analyses using embryonic myosin heavy chain (eMyHC) as a marker for early regenerated myotubes and found widespread and robust eMyHC expression in TEAD1-Tg muscle regenerates, which is in contrast to Wt regenerates, for which eMyHC expression is more sparse and less robust ([Figure 5I--J^i^](#fig5){ref-type="fig"}). At 7 and 14 dpi, regenerative myofibers with centrally located myonuclei were present in both Wt and TEAD1-Tg samples, with no evidence of fibrosis or immune cell infiltration ([Figure 5C--F^i^](#fig5){ref-type="fig"}), demonstrating that TEAD1-Tg muscle retains full regenerative capacity. Consistent with the accelerated formation of new myofibers at 3 dpi, when we quantified the sizes of regenerated myofibers at 7 dpi, we found both fiber area and diameter to be significantly increased in TEAD1-Tg muscle regenerates compared to Wt ([Figure 5G--H](#fig5){ref-type="fig"}). By 14 dpi, no difference in fiber size was detected. Maturation of regenerative myofibers is normal in TEAD1-Tg TA muscles as fiber sizes were no different compared to Wt at 35 dpi ([Figure 5G--H](#fig5){ref-type="fig"}). These data demonstrate that TEAD1-Tg muscle features accelerated kinetics of initial myotube formation upon injury. Despite this accelerated regeneration process and super-numeral SCs, we are surprised that no myofiber hypertrophy resulted from the injury-induced regenerative myogenesis. We therefore suggest that these two processes are separable.10.7554/eLife.15461.008Figure 5.TEAD1-Tg muscle exhibits faster regeneration than Wt muscle upon injury with cardiotoxin.(**A--F^i^**) H and E stains of Wt (**A--A^i^**, **C--C^i^**, **E--E^i^**) and TEAD1-Tg (**B--B^i^**, **D--D^i^**, **F--F^i^**) TA muscle 3 days (3 dpi, **A--B^i^**), 7 days (7 dpi, **C--D^i^**), or 14 days (14 dpi, **E--F^i^**) after injury with cardiotoxin (CTX). Panels **Ai--Fi** show a higher magnification of the regenerating muscle (indicated by arrows and central nuclei). A lack of arrows in **A^i^** is due to a lack of identifiable young fibers at that stage in Wt muscle. **G--H**) Quantification of fiber area (**G**) and fiber diameter (**H**) for 7 dpi, 14 dpi, and 35 dpi. **I--J^i^**) IF of embryonic myosin heavy chain (eMyHC, **I--J^i^**) localized to regenerating fibers in Wt (**I--I^i^**) and TEAD1-Tg (**J--J^i^**) TA muscles 3 days after injury by CTX. Images **I^i^** and **J^i^** show a zoomed-in region indicated by the white boxes in images **I** and **J**. n \> 3 mice for all samples quantified. p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.008](10.7554/eLife.15461.008)

We applied an additional injury paradigm via the myotoxin BaCl~2~, which is thought to display less toxicity towards SCs compared to cardiotoxin ([@bib4]; [@bib14]), to more accurately elucidate the rapid kinetics of initial muscle repair (3, 5 and 7 dpi; [Figure 6A--H^i^](#fig6){ref-type="fig"}). Confirming our observations made with the cardiotoxin injury paradigm ([Figure 5](#fig5){ref-type="fig"}), we found significantly larger myofibers in TEAD1-Tg compared to Wt control regenerates demonstrated by increased fiber area ([Figure 6I](#fig6){ref-type="fig"}) and diameter ([Figure 6J](#fig6){ref-type="fig"}) at both 5 and 7 dpi. We conducted IF analyses of myogenic marker expression to examine the timing of myogenic differentiation in more detail ([Figure 6K--R](#fig6){ref-type="fig"}). Myogenin is a terminal marker of myogenic differentiation and its expression gradually increases from 3 to 5 dpi; while eMyHC expression typically initiates at 3 dpi, peaks at 4 and 5 dpi, and then diminishes by 6 to 7 dpi, at which point it becomes replaced by adult myosin heavy chain isoforms. Consistent with the earlier detection of new myotubes by 3 dpi by histology in TEAD1-Tg compared to Wt regenerates ([Figure 5A,B](#fig5){ref-type="fig"}), we found both Myogenin and eMyHC to be increased at this early regeneration time point in TEAD1-Tg compared to Wt samples ([Figure 6K--N](#fig6){ref-type="fig"}). By 5 dpi, while the number of Myogenin^+^ cells is still increased in TEAD1-Tg compared to Wt regenerates ([Figure 6O--P](#fig6){ref-type="fig"}), eMyHC expression is already reduced in TEAD1-Tg regenerative myofibers ([Figure 6R](#fig6){ref-type="fig"}) compared to the 3 dpi time point ([Figure 6N](#fig6){ref-type="fig"}) and the peak expression observed in Wt 5 dpi skeletal muscle regenerates ([Figure 6P](#fig6){ref-type="fig"}), suggesting it is already being replaced by more mature myosins. Taken together, these data demonstrate acceleration of skeletal muscle regeneration by super-numeral SCs.10.7554/eLife.15461.009Figure 6.TEAD1-Tg muscle exhibits faster regeneration than Wt muscle upon injury with BaCl~2~.(**A--H^i^**) H and E stains of Wt (**A--D^i^**) and TEAD1-Tg (**E--H^i^**) TA muscle 3 days (**B--B^i^**, **F**--**F^i^**), 5 days (**C--C^i^**, **G--G^i^**), or 7 days (**D--D^i^**, **H--H^i^**) after injury with BaCl~2~ or uninjured (**A--A^i^**, **E--E^i^**). Images **A^i^--H^i^** are higher magnification views of regenerating areas of muscle (regenerating fibers indicated by black arrows). **I--J**) Quantification of fiber area (**I**) and fiber diameter (**J**) for 5 days and 7 days after BaCl~2~ injury. **K--R**) IF images show myogenin (green) and DAPI (blue; **K**,**M**,**O**,**Q**) or embryonic myosin heavy chain (green) with laminin (red; **L**,**N**,**P**,**R**) localized to regenerating fibers in Wt (**K--L**, **O--P**) and TEAD1-Tg (**M--N**, **Q--R**) TAs 3 days and 5 days after BaCl~2~ injury. For quantification of fiber number and diameter n=3 mice were used. p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.009](10.7554/eLife.15461.009)

Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts {#s2-5}
----------------------------------------------------------------------------------------------------------------------

SCs represent a self-renewable reservoir of stem cells able to repeatedly provide myonuclei for muscle repair. To test if super-numeral SCs of TEAD1-Tg muscle can self-renew, we assayed for their capacity to support repeated regeneration bouts. For this, we injured the TA muscles of TEAD1-Tg and Wt littermates three times, allowing 5 weeks between injuries for complete regeneration ([Figure 7A](#fig7){ref-type="fig"}). Indeed, robust regeneration in both singly ([Figure 7B,D](#fig7){ref-type="fig"}) and triply ([Figure 7C,E](#fig7){ref-type="fig"}) injured TA muscles of both Wt and TEAD1-Tg mice were observed. We did not detect any excess collagen deposition in TEAD1-Tg TA muscles after one or three injury-induced regeneration bouts compared to Wt TA muscles ([Figure 7F--I](#fig7){ref-type="fig"}). These data demonstrate that super-numeral SCs of TEAD1-Tg skeletal muscle retain regenerative capacity after repeated injury and suggest that these SCs self-renew (to maintain their numbers as cells are recruited for fusion into myofibers). To test if these SCs participated in and contributed to the regeneration process prior to replenishing the Pax7^+^ muscle reserve cell pool, we interrogated whether Pax7^+^ SCs of skeletal muscle regenerates had proliferated by administering EdU during the proliferative period of the regeneration process to mark cells in S-Phase. Two weeks after injury, we could readily detect EdU^+^/Pax7^+^ cells in both Wt and TEAD1-Tg samples ([Figure 7J--K](#fig7){ref-type="fig"}). We did not detect any statistically significant differences in the percentages of EdU^+^/Pax7^+^ SCs between Wt and TEAD1-Tg samples ([Figure 7L](#fig7){ref-type="fig"}). These data further support that SCs of TEAD1-Tg mice are self-renewing. Furthermore, we not only detected sublaminal Pax7^+^ SCs in singly-, but also in triply-injured TA muscles of both TEAD1-Tg and Wt littermates ([Figure 7M--P](#fig7){ref-type="fig"}). Quantification of the number of Pax7^+^ SCs revealed that super-numeral SCs are maintained in skeletal muscle regenerates of TEAD1-Tg mice ([Figure 7Q--R](#fig7){ref-type="fig"}), though the magnitude of the typical 5-fold increase in SCs in uninjured muscle is reduced to \~3.5-fold after one and \~3-fold after three injuries ([Figure 7R](#fig7){ref-type="fig"}). This reduction in the magnitude of the SC hyperplasia after three injuries could reflect a diminished self-renewal capacity. All together, these data demonstrate that super-numeral SCs of TEAD1-Tg muscle can self-renew and maintain the tissue's high capability for regeneration after repeated traumatic insults.10.7554/eLife.15461.010Figure 7.SC hyperplasia persists through multiple injuries.Adult mouse TA muscles were injured with BaCl~2~ multiple times with 35-day regeneration periods between injuries as indicated (**A**). This injury paradigm applies to panels **B--I**, **M--P**) H and E stains show muscle after 35 days of regeneration following one injury (**B**,**D**) or 3 injuries (**C**,**E**) for Wt (**B**,**C**) or TEAD1-Tg muscle (**D**,**E**). (**F--I**) Sirius Red stains show the connective tissue after 35 days of regeneration following one injury (**F**,**H**) or 3 injuries (**G**,**I**) for Wt (**F**,**G**) or TEAD1-Tg muscle (**H**,**I**). (**J--L**) Wt (**J**) and TEAD1-Tg (**K**) TA muscles were injured with CTX and regenerated for 2 weeks. EdU was given on days 2--5 of regeneration. IF of Pax7 (green), laminin (red), EdU (white), and counterstained with DAPI (blue) allowed for quantification of sublaminal Pax7 and EdU positive cells (**L**). Myonuclei in images are EdU positive but reduced in intensity due to larger nuclear volume. **M--P**) Numbers of Pax7 expressing cells were assessed by IF of Pax7 (green) and laminin (red), counterstained with DAPI (blue) after 35 days of regeneration following one injury (**M**,**O**) or 3 injuries (**N**,**P**) for Wt (**M**,**N**) or TEAD1-Tg muscle (**O**,**P**) and is quantified as SC averages per area (**Q**) and fold increase relative to Wt (**R**). Uninjured data from [Figure 2](#fig2){ref-type="fig"} displayed for comparison. n \> 3 adult mice for all measurements, p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.010](10.7554/eLife.15461.010)

Dystrophic pathology is ameliorated in *mdx*; TEAD1-Tg skeletal muscle {#s2-6}
----------------------------------------------------------------------

To challenge the regenerative capacity of TEAD1-Tg muscle further, we subjected the tissue to a state of chronic degeneration. To accomplish this, we bred TEAD1-Tg mice to the *mdx* mouse, a mouse model of Duchenne muscular dystrophy, which is the most severe form of the muscle wasting diseases. These mice lack the sarcolemmal protein dystrophin, which results in greatly destabilized muscle fibers and thus, chronically injured and regenerating muscle tissue, evidenced by the presence of many regenerative myofibers with centrally located nuclei, a hallmark pathological feature of this disease. Histological analyses revealed greatly reduced numbers of regenerative muscle fibers in *mdx*; TEAD1-Tg compared to *mdx* TA muscles of 2--3 months old littermates ([Figure 8A--B](#fig8){ref-type="fig"}). The percentage of fibers with central nuclei was reduced from \~55% in Wt to less than 20% in TEAD1-Tg muscles ([Figure 8C](#fig8){ref-type="fig"}), implying less degeneration in *mdx*; TEAD1-Tg muscle. We also noted a concomitant significant reduction in myofiber hypertrophy, a secondary pathological feature of the *mdx* dystrophy model ([Figure 8D--E](#fig8){ref-type="fig"}). To further probe the extent of improvement of the dystrophic phenotype, we assayed for fibrosis, another histological hallmark feature of skeletal muscle dystrophy. Trichrome stainings revealed a significant reduction in fibrotic area in *mdx*; TEAD1-Tg compared to *mdx* muscle ([Figure 8F--G](#fig8){ref-type="fig"}; quantification in [Figure 8H](#fig8){ref-type="fig"}). Dystrophic muscle fibers have an altered sarcolemmal permeability, which can be assessed via Evans Blue Dye (EBD) uptake. While large numbers of EBD positive fibers where detected in *mdx* muscle, EBD incorporation by fibers of *mdx*; TEAD1-Tg mice was largely stunted ([Figure 8I--J](#fig8){ref-type="fig"}; quantification in [Figure 8K](#fig8){ref-type="fig"}). The absence of evidence for worsened muscle pathology and by contrast, an amelioration of the dystrophy argues for SCs being functional in dystrophic TEAD1-Tg muscle. Lastly, we assayed for SCs in dystrophic muscle of *mdx* and *mdx*; TEAD1-Tg littermates ([Figure 8L--M](#fig8){ref-type="fig"}). Quantification of Pax7^+^ cells revealed an \~2-fold increase in SCs in *mdx*; TEAD1-Tg mice ([Figure 8N](#fig8){ref-type="fig"}). While less dramatic compared to the fold increase observed in healthy muscle, the SC hyperplasia in dystrophic muscle is quite substantial considering the baseline SC numbers are already increased due to higher SC proliferation in the chronically de- and regenerating environment. The magnitude of the SC hyperplasia is potentially also affected by impaired dystrophin-deficient SCs ([@bib12]).10.7554/eLife.15461.011Figure 8.Pathologies of muscular dystrophy are ameliorated by TEAD1-Tg expression.Histology, IF analyses, and qRTPCR on dystrophic muscle from *mdx* mice modeling chronic injury. **A--C**) Asterisks in H and E stained muscle sections indicate regenerated fibers in *mdx* (**A**) and *mdx*; TEAD1-Tg mice (**B**). The percent of fibers that are regenerative is quantified for each genotype in **C**. **D--E**) The fiber area (**D**) and fiber diameter (**E**) for *mdx* or *mdx*; TEAD1-Tg TA muscle is also quantified. **F--H**) Trichrome staining was employed to label fibrotic areas in *mdx* (**F**) or *mdx*; TEAD1-Tg (**G**) TA muscle. Percent fibrotic area was quantified (**H**). **I--K**) Membrane leakage was assessed by Evan's Blue Dye incorporation into the myofibers of *mdx* (**I**) or *mdx*; TEAD1-Tg (**J**) TA muscle. Positive fibers per area were quantified (**K**). (**L--N**) Numbers of Pax7 expressing cells were assessed by IF of Pax7 (green), and laminin (red), counterstained with DAPI (blue) in *mdx* (**L**) or *mdx*; TEAD1-Tg (**M**). TA muscles are quantified as fold increase relative to *mdx* in **N**. Utrophin (Utrn) expression was quantified in *mdx* or *mdx*; TEAD1-Tg TA muscle via qRTPCR (**O**). n \> 3 adult mice for all measurements, p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.011](10.7554/eLife.15461.011)

Whether increased SCs, altered myofiber properties, or both contribute to the amelioration of the dystrophic pathology in *mdx*; TEAD1-Tg muscle is unclear. Besides differing in their contractile properties, slow-twitch muscle features higher utrophin levels compared to fast-twitch muscle ([@bib17]). Utrophin can functionally substitute for dystrophin ([@bib42]). Since TEAD1-Tg muscle features a transition to the slow contractile muscle protein phenotype, we decided to investigate utrophin expression in *mdx*; TEAD1-Tg skeletal muscle. Quantitative PCR revealed an \~3-fold increase in utrophin expression in *mdx*; TEAD1-Tg compared to *mdx* muscle samples ([Figure 8O](#fig8){ref-type="fig"}). Additionally, we assayed for revertant myofibers via anti-dystrophin IF. No increased reversion rates were found in *mdx*; TEAD1-Tg compared to *mdx* muscle samples (data not shown). These data suggest that stabilization of the sarcolemma via utrophin up-regulation contributes to amelioration of the dystrophic muscle pathology of *mdx*; TEAD1-Tg mice.

Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle {#s2-7}
------------------------------------------------------------------

The HA-tagged TEAD1 transgene is under the control of the muscle creatine kinase promoter and presumed to be exclusively expressed by the myofiber and not its associated SCs. To confirm this, we determined the expression of the TEAD1 transgene with respect to SCs or the myofiber plasmalemma by co-IF for HA and Pax7 in TEAD1-Tg skeletal muscle ([Figure 9A--B^iii^](#fig9){ref-type="fig"}). We found no overlap of HA^+^ and Pax7^+^ nuclei ([Figure 9A--A^iii^](#fig9){ref-type="fig"}). All HA expression was localized below the dystrophin^+^ domain revealing that the only TEAD1 expressing nuclear species are those within the myofiber ([Figure 9B--B^iii^](#fig9){ref-type="fig"}). To more rigorously probe MCK promoter-controlled TEAD1 transgene expression, we grew myoblasts in heterogeneous cultures containing both proliferative myoblasts as well as differentiated myocytes. We then assayed for transgene expression (HA) in post-mitotic differentiated myocytes (Myogenin^+^). All HA staining was contained within the domain of Myogenin^+^ cells ([Figure 9C](#fig9){ref-type="fig"}). These data demonstrate that the TEAD1 transgene is not expressed by proliferative myoblasts but only by differentiated myogenic cells. Reciprocally, we probed for TEAD1 transgene expression (via HA) in Pax7^+^ reserve cells. As expected, transgene expression was excluded from the domain of Pax7^+^ reserve cells ([Figure 9C](#fig9){ref-type="fig"}).10.7554/eLife.15461.012Figure 9.SC hyperplasia derives from cell-cell signaling between the myofiber and SCs.(**A--A^iii^**) IF images of TEAD1-Tg TA adult muscle show Pax7 expressing SCs (green; **A**) and HA tagged TEAD1 (red; **A^i^**), and are merged in image (**A^ii^**) and a zoomed-in merged image (**A^iii^**) to show that these genes are expressed in distinct compartments. **B--B^iii^**) IF of HA-TEAD1 (red, **B^i^**) and dystrophin (green, **B**) show that the TEAD1 transgene is expressed in nuclei of the myofiber in TA adult muscle. Transgene expression was also queried by HA colocalization with Myogenin (Myog) and Pax7-expressing reserve cells in differentiated cell culture experiments after 3 and 5 days of differentiation, respectively (**C**). (**D--J**) In vitro differentiation of myoblasts derived from Wt (**D--F**) or TEAD1-Tg (**G--I**) hind limb muscle shows equivalent expression of MyoD (**D**,**G**; green), Myogenin (**E**,**H**; green), and myosin heavy chain (**F**,**I**; green) and is quantified in **J** (n\> 480 cells for all). (**K--M**) Cultures of Wt (**K**) or TEAD1-Tg (**L**) myoblasts show equivalent EdU label (green), which is quantified in M (n\>375 cell for each). **N--P**) Muscle fibers and associated SC were isolated and grown in culture for 72 hr with EdU in the growth media after 24 hr in culture. A minimum number of 50 fibers were quantified. Cell clones labeled with Pax7 (green), DAPI (blue), and/or EdU (red) can be observed on isolated muscle fibers from Wt (**N**) or TEAD1-Tg (**O**) mice and are quantified in **P**. The average number of Pax7-positive cells (T0) and the average number of clones on muscle fibers after 72 hr (T72) in growth media are quantified in **Q**. Clone sizes for TEAD1-Tg and Wt fibers at 72 hr post myofiber isolation in R (n=3 mice each). After 72 hr in culture, the ratio of self-renewing SCs to differentiating cells within these clones is quantified in **U** (n\>150 clone) for both Wt (**S**) and TEAD1-Tg (**T**) isolated fibers cultured in 10% FBS/ DMEM. p\<0.05 represented by (\*), p\<0.005 represented by (\*\*), p\<0.0005 represented by (\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.012](10.7554/eLife.15461.012)

The above results predict that the hyper-proliferation of SCs in TEAD1-Tg skeletal muscle ([Figure 3](#fig3){ref-type="fig"}) depends on their associated differentiated progeny, in which the TEAD1 transgene is expressed via the MCK promoter, i.e. the myofiber. To test this prediction, we performed in vitro myoblast culture experiments either in the absence or presence of the associated TEAD1-Tg myofiber ([Figure 9D--U](#fig9){ref-type="fig"}). First, we cultured primary myoblasts derived from either TEAD1-Tg or Wt hind limb muscles ([Figure 9D--M](#fig9){ref-type="fig"}). We detected no differences in the differentiation or proliferation capacities between them. Upon serum starvation, myoblasts from either genotype readily differentiated as indicated by early (MyoD), late (Myogenin), and terminal (myosin heavy chain) differentiation marker expression ([Figure 9D--I](#fig9){ref-type="fig"}; quantified in[Figure 9J](#fig9){ref-type="fig"}). Proliferation assays using EdU incorporation, also revealed no differences between primary myoblasts from TEAD1-Tg and from Wt muscles ([Figure 9K--L](#fig9){ref-type="fig"}; quantified in [Figure 9M](#fig9){ref-type="fig"}). To determine if the TEAD1-Tg myofiber affects proliferation of its attached cohort of SCs, we cultured single myofibers from EDL muscles of TEAD1-Tg and Wt littermates and determined SC proliferation via cumulative marking of Pax7^+^ cells in S-Phase via EdU ([Figure 9N--O](#fig9){ref-type="fig"}; quantification in [Figure 9P](#fig9){ref-type="fig"}). The majority (\~92%) of SCs on Wt fibers proliferated. The proportion of proliferating SCs was significantly increased on TEAD1-Tg myofibers, as all Pax7^+^ cells are positive for EdU ([Figure 9P](#fig9){ref-type="fig"}). No statistically significant differences in apoptotic rates were found via anti-Caspase-3/Pax7 co-IF staining (\~0.8±1.4% versus \~3.2±1% Caspase3^+^/Pax7^+^ cells on Wt and TEAD1-Tg fibers, respectively; p\>0.05). To determine the effect of the increased proliferation rate on SC clone formation, we quantified SCs on single myofibers at t=0 hr, and number of clones as well as clone size at t=72 hr on both Wt and TEAD1-Tg myofibers ([Figure 9Q--R](#fig9){ref-type="fig"}). As expected, we found significantly increased numbers of SCs associated with freshly isolated TEAD1-Tg compared to Wt myofibers ([Figure 9Q](#fig9){ref-type="fig"}). At t=72 hr, the number of SC clones vastly exceeded that of the starting number of SCs for both Wt and TEAD1-Tg samples suggesting that some clones split into 2 or more clones ([Figure 9Q](#fig9){ref-type="fig"}). Yet, significantly greater numbers of cells were found per clone on TEAD1-Tg compared to Wt fibers ([Figure 9R](#fig9){ref-type="fig"}). This evidence suggests that increased proliferation yields larger clones on TEAD1-Tg cultured myofibers rather than fusion of clones derived from multiple SCs, as clone fracturing occurs more frequently than clone fusion and at similar rates between Wt and TEAD1-Tg samples ([Figure 9N--R](#fig9){ref-type="fig"}). We next assayed cells of these clones for differentiating (MyoD^+^), expanding (MyoD^+^/Pax7^+^), and self-renewing (Pax7^+^) cell fates ([Figure 9S--T](#fig9){ref-type="fig"}). Quantification revealed that hyper-proliferation of SCs on TEAD1-Tg myofibers does not alter the relative distributions of these cell fates, but instead involves a proportional increase in the sizes of each fraction ([Figure 9U](#fig9){ref-type="fig"}). These data further confirm the SC self-renewal capacity in vivo ([Figure 7](#fig7){ref-type="fig"}).

A model of increased proliferation yielding a larger number of progeny, and consequently more SCs, is consistent with our in vivo postnatal proliferation rates ([Figure 3](#fig3){ref-type="fig"}) and explains the hyperplasia phenotype. We conclude that SC hyperplasia of TEAD1-Tg skeletal muscle is a non-cell autonomous phenomenon, which involves the coordinated scaling of the expanding, differentiating, and self-renewing myogenic cell populations.

Discussion {#s3}
==========

Here we show a novel mouse model featuring, at its core, a robust 5- to 6-fold increase in the number of quiescent SCs, accelerated kinetics of muscle repair, amelioration of the muscular dystrophy pathology, and non-cell autonomous induction of SC hyperplasia. Because SC hyperplasia occurs without myofiber hyperplasia or hypertrophy, scaling between initial SC pool size and muscle fiber volume/length can be uncoupled, or at least altered. The teleological ramification of our findings is discussed.

TEAD1-Tg mice: A novel mouse model for SC hyperplasia {#s3-1}
-----------------------------------------------------

SC hyperplasia in TEAD1-Tg mice is universal among the muscle groups analyzed, including pre-dominantly fast- or pre-dominantly slow-twitch muscle groups. Since the TEAD1-Tg features a transition to the slow-twitch muscle contractile phenotype, i.e. loss of type IIX fibers ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib53]), the pervasiveness of the SC hyperplasia among the different muscles analyzed is particularly noteworthy. Higher SC densities have been found in slow-twitch compared to fast-twitch muscles ([@bib15]; [@bib47]; [@bib9]). As such, the fast- to slow-twitch fiber transition may account for the SC hyperplasia in TEAD1-Tg mice. However, the pre-dominantly slow-twitch soleus muscle, which is devoid of type IIX fibers, features the largest increase (6-fold) in SCs in TEAD1-Tg mice. Hence, the increase in SCs cannot solely be a 'passenger effect' of the fast- to slow-twitch fiber transition. The SC hyperplasia originates at the time of peak TEAD1 transgene expression around PN 14d ([Figure 3](#fig3){ref-type="fig"}) and eventually features normal quiescent adult SCs indistinguishable from their Wt counterparts ([Figure 4](#fig4){ref-type="fig"}). In particular, we utilized this new mouse model of SC hyperplasia to investigate whether an increase in the physical number of stem cells had any impact on skeletal muscle regeneration and discovered faster regeneration kinetics in TEAD1-Tg mice ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). The SC hyperplasia persists through multiple and chronic injuries ([Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}) and notably, derives from cell-cell signaling between the myofiber and the SCs ([Figure 9](#fig9){ref-type="fig"}). All together, these features uniquely prime the TEAD1-Tg mouse model for the future discovery of the elusive signaling pathway(s) regulating muscle stem cell number.

Though SC hyperplasia is not well studied, other genetic or pharmacologically induced mouse models have reported an expansion of the SC pool in adult mice. For example, skeletal muscle mutant for Collagen VI has an \~2.4-fold increase in SCs. As mutations in this gene cause myopathy or muscular dystrophy in humans ([@bib23]), Collagen VI mutant mice also feature dystrophic muscle, which leads to SC activation as evidenced by increased proliferation and apoptosis ([@bib54]). Hence an increase in SCs is also observed in *mdx* mice ([@bib5]). As such, this model features impaired regeneration and a failure to sustain the SC hyperplasia during injury-induced regenerative myogenesis ([@bib54]). Likewise, ectopic application of Wnt7a in adult regenerative muscle drives an \~2-fold expansion of proliferative SCs. No accelerated kinetics of muscle repair were noted but muscles featured both hypertrophy and hyperplasia ([@bib24]). Subsequently, Wnt7a was shown to directly act on the myofiber for induction of hypertrophy ([@bib55]). The expansion of SCs by Wnt7a can be further increased by the co-application with fibronectin. Whether the additional SC increase impacted myofiber hypertrophy and/or hyperplasia was not reported ([@bib2]). The source of Wnt7a in skeletal muscle is unresolved. Also, the Wnt7a-induced increase in SCs may be indirectly coupled to the myofiber hypertrophy, precluding a concrete conclusion about the signaling for the SC expansion.

While informative, the above mouse models are not useful in elucidating the molecular regulation underlying initial scaling of SC pool size during the perinatal period. They feature many distinct aspects including a less robust increase of SCs, a non-developmental origin of SC increase, overall muscle tissue hypertrophy and/or failure to generate a stably quiescent pool of adult SCs. The TEAD1 transgene induced SC hyperplasia is of the greatest known magnitude to-date, stably established during early postnatal development and features a normal adult quiescent phenotype. The timing of the SC increase in TEAD1-Tg muscle is particularly noteworthy and should incite new investigations of the aforementioned mouse models during the early postnatal period to further unravel this fundamental \'stem cell scaling\' process in skeletal muscle. Furthermore, while myofiber-specific TEAD1 overexpression reveals a surprising plasticity of the muscle stem cell niche to harbor greatly increased SCs, we do not know if there are any functional requirements for the Tead transcription factor family in the regulation of SC number. Further studies of Tead loss-of-function mouse models are needed.

Developmentally induced SC hyperplasia {#s3-2}
--------------------------------------

The activity of early postnatal SCs is markedly different from their adult counterparts. Adult SCs are kept in a quiescent state, while early postnatal SCs are highly proliferative providing differentiated myonuclei for muscle growth as they progressively exit the cell cycle to be set aside as quiescent stem cells during the first three weeks after birth ([@bib27]; [@bib60]). The signals that orchestrate the SC transition from the proliferative to the quiescent state are unknown but likely entail both 'proliferation' and 'quiescence' cues from the local niches leading to the formation of an adult muscle stem cell pool of defined size. Super-numeral SCs and increased SC proliferation were first detected in TEAD1-Tg muscle during this early postnatal period at 2 weeks after birth ([Figure 3](#fig3){ref-type="fig"}). Since TEAD1-Tg muscle is not hypertrophic and does not accumulate more nuclei than Wt ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), a \'Stop\' signal must exist, and be still intact in TEAD1-Tg mice to prevent further fusion by excessive SCs. Thus, we propose that the extra rounds of SC proliferation are a selectively symmetric expansion of the stem cell pool. The likely mechanism driving the SC hyperplasia is over-expression or prolonged expression of physiologically normal 'proliferation' factor(s), or reduced expression of 'quiescence' factor(s) in early postnatal TEAD1-Tg muscle. Therefore, this animal model may also be useful to uncover the physiological signaling underlying the complex transition from a proliferative juvenile progenitor to a quiescent adult stem cell.

Reduced SC hyperplasia of regenerated muscle {#s3-3}
--------------------------------------------

Applying EdU to monitor SC proliferation both in vivo ([Figure 7](#fig7){ref-type="fig"}) and in vitro ([Figure 9](#fig9){ref-type="fig"}), we found super-numeral SCs of TEAD1-Tg muscle to be self-renewing stem cells. This conclusion is further supported by the observation that the TEAD1 transgene induced SC hyperplasia is maintained even over several injury-induced regeneration cycles ([Figure 7](#fig7){ref-type="fig"}). Of note, the magnitude of the hyperplasia is slightly lessened with multiple bouts of regeneration. It is possible that the SC self-renewal capacity is slightly reduced in TEAD1-Tg mice. It is also possible that the regenerating tissue lacks the ability to promote SC hyperplasia to the same degree as the early postnatal myofiber. The adult niche is destroyed by injury leading to a transient loss of the TEAD1-expressing cell, i.e. the muscle fiber. This is in contrast to the 'intact' early postnatal niche, which drives the establishment of super-numeral SCs in TEAD1-Tg mice and features intimate contact between the TEAD1-expressing muscle fiber and its SCs. Moreover, there appear to be differences in the regulation of proliferating early postnatal versus quiescent adult SCs. Temporally-controlled inactivation of Pax7 in SCs shortly after birth leads to an immediate dramatic loss in regenerative capacity while inactivation in the adult leads to a slow progressive loss of SCs, which is reflected by normal regeneration over the short-term and impaired regeneration over the long-term ([@bib19]; [@bib27]). It is possible that early postnatal SCs are uniquely primed to receiving proliferation and quiescence cues from their local niches, which leads to the formation of a properly proportioned adult muscle stem cell pool. Such cues may be expressed at a higher level or for a longer period of time in the developing muscles than in adult regenerating muscles of TEAD1-Tg mice. Or, the adult SC niche may be more restrictive to proliferation, and thus limiting to the extent of re-establishment of the SC hyperplasia during regeneration. For example, the stiffness of the extracellular matrix from skeletal muscle has been demonstrated to increase with age ([@bib61]), and substrate elasticity has been shown to affect the regenerative competence of SCs ([@bib16]). Along this line of thought, it is interesting to note that neither developmental nor regenerative muscles of TEAD1-Tg mice produce hypertrophy despite the SC hyperplasia ([Figures 1](#fig1){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). It seems reasonable that upon acquiring the 'correct' number of myonuclei, to efficiently support the transcriptional and metabolic needs, the myofiber sends \'dominant\' signal(s) to prevent additional fusion by SCs, and possibly to stop SC proliferation. A longer period of SC proliferation during early postnatal development versus adult regeneration could be the basis for the plasticity of the magnitude of the SC hyperplasia.

Ameliorated dystrophy in *mdx*; TEAD1-Tg mice {#s3-4}
---------------------------------------------

The muscle histopathology found in the *mdx* mouse model was significantly mitigated in the TA muscle of *mdx*; TEAD1-Tg mice ([Figure 8](#fig8){ref-type="fig"}). This finding can likely be accounted for based on a TEAD1-induced slow-oxidative phenotype in both fast and slow-twitch muscles, which we determined previously by high-resolution electrophoretic separation and quantification of native myosin heavy chain isoforms and confirmed here by IF ([@bib53]). This notion is consistent with previous studies demonstrating that slow-twitch oxidative fibers in human and murine dystrophic muscles are less susceptible to the degenerative outcome of muscular dystrophies than are fast-twitch fibers ([@bib36]; [@bib59]; [@bib10]). More recent therapeutic efforts shown to mitigate the dystrophic pathology in the *mdx* model have utilized transgenic (calcineurin, peroxisome proliferator-activated receptor-γ coactivator-1α, AMP-activated protein kinase, Kruppel-like factor 15) or pharmacological (Resveratol, AICAR, GW501516, Wnt7a) mediators, all previously shown to remodel dystrophic muscle to reflect a greater proportion of slow-oxidative fiber-types ([@bib51]; [@bib8]; [@bib20]; [@bib21]; [@bib52]; [@bib30]; [@bib56]; [@bib37]). It is therefore conceivable that the TEAD1-Tg-induced slow-oxidative myofiber phenotype ameliorates dystrophic pathology in *mdx* muscle in similar fashion to the aforementioned studies. In particular, utrophin, which can functionally substitute for dystrophin, is elevated in slow-twitch when compared to fast-twitch muscle ([@bib17]; [@bib42]). Elevated *utrophin* transcript levels in *mdx*; TEAD1-Tg muscle are a highly likely contributor to the betterment of the dystrophic pathology ([Figure 8](#fig8){ref-type="fig"}). Additional mechanisms are likely at play. Calcineurin is a direct transcriptional activator of utrophin and skeletal-muscle specific overexpression results in increased utrophin protein levels and results in amelioration of the dystrophic pathology ([@bib51]). Yet, the extent of the observed amelioration is significantly smaller when compared to the *mdx*; TEAD1-Tg model. Additional properties of the myofiber affected by the TEAD1 transgene could further protect the fiber from degeneration. It is also possible that the increased number of SCs in *mdx*; TEAD1-Tg muscle contributes to a more speedy repair process, thereby stabilizing the dystrophic muscle. Or, both mechanisms may contribute. Additionally, it would be of great interest to quantify SCs in the murine models above to determine if their numbers are increased as well, which could also potentially contribute to an ameliorated disease state.

SC hyperplasia without muscle hypertrophy {#s3-5}
-----------------------------------------

It is conceivable that the size of the resident stem cell pool could be modulated with, and thus, be directly linked to the size of tissue, for example via physical expansion or reduction of available stem cell niches. To extend this idea, it is of interest to consider the exquisite molecular mechanisms that have evolved to initially establish and then maintain proper skeletal muscle tissue size. Signaling pathways including Hippo, IGF-1, Wnt, calcium (via NFAT), and TGF-β contribute to the regulation of myofiber size and number. In particular, the TGF-β family member myostatin and its receptor activin receptor type-IIB (ActRIIB) play prominent roles, as both genetic inactivation of myostatin and ActRIIB antagonism result in a double muscling phenotype in mice with both hyperplasia and hypertrophy ([@bib35]; [@bib64]; [@bib26]). However, it remains controversial whether a corresponding SC increase accompanies and is required for the increase in muscle mass by inhibition of myostatin signaling ([@bib34]; [@bib58]; [@bib64]; [@bib25]). Inactivation of ActRIIB specifically in the myofiber causes myofiber hypertrophy arguing against myofiber size regulation being dependent on the SC pool ([@bib25]). Likewise, myostatin inhibition has been shown to result in skeletal muscle hypertrophy in the absence of satellite cell activity ([@bib1]). Canonical Wnt signaling has been implicated in regulating myogenic progenitor and myofiber number during fetal myogenesis and muscle repair after injury ([@bib22]; [@bib38]; [@bib44]). Similarly, calcium signaling via NFAT proteins has been implicated in regulating skeletal muscle size ([@bib48]). In our previous work, we found both Wnt and NFAT signaling to be significantly reduced in TEAD1-Tg muscle ([@bib53]). Yet, we did not find muscle tissue size to be altered ([Figure 1](#fig1){ref-type="fig"}). This apparent discrepancy can likely be attributed to the late onset of MCK promoter driven TEAD1 transgene expression, which happens after muscle differentiation. Thus, neither differentiation nor fusion is affected in these mice. And the non-autonomous induction of super-numeral SCs results in the uncoupling of the molecular regulation of SC number from muscle size in TEAD1-Tg mice. Similarly, muscle groups of different ontology appear to maintain different SC to muscle nuclei ratios, i.e. branchiomeric muscles have significantly fewer SCs compared to somite-derived muscles ([@bib41]). Still, muscle fibers and their associated cohort of SCs have co-evolved to maintain a relatively fixed ratio. While the evolutionary selection pressures for both processes are unknown they are of great biological curiosity.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

hTEAD1 transgenic mice were previously described ([@bib53]). Age-matched C57BL/6 siblings served as Wt controls. *mdx* mice (ID: 001801) were obtained from the Jackson Laboratory (ME). Injury with cardiotoxin (10 µM, Sigma C9759) to the TA (after anesthesia) used 50 µl for adult (\>2 months) mice. For injury by BaCl~2~ (after anesthesia), TA muscles were injected with 25 µl of 1.2% (w:v) Barium Chloride (Sigma 217565) in PBS. For multiple rounds of injury, TA muscles were injected with 25 μl of BaCl~2~ for each injury and allowed to regenerate for 35 days between injuries. EdU (Invitrogen; CA) was administered as previously described ([@bib27]). BrdU (5-bromo-2'-deoxyuridine, Sigma B5002) was provided in drinking water (0.8 mg/mL) for 30 consecutive days. All procedures were approved by IACUC.

PCR genotyping and quantitative PCR (qPCR) {#s4-2}
------------------------------------------

For adult animals, tail DNA was used for genotyping by PCR. For perinatal mice, toe DNA was used. DNA was extracted using the ExtractN'Amp kit (Sigma XNAT2) following the manufacturer's instructions. PCR reactions were carried out using GoTaq polymerase (Promega M8291) with buffers supplied by the manufacturer with 0.1 mM dNTPs and 2.5 mM MgCl~2~. PCR products were resolved in a 2% agarose gel, stained with 0.5 µg/mL ethidium bromide (Gibco 15585011), and digitally imaged with a Bio-Rad Gel Doc system for record keeping. Primer sequences, product sizes, and PCR conditions are in [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.15461.013Table 1.PCR genotyping and RT primers, and conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.15461.013](10.7554/eLife.15461.013)GeneForward primerReverse primerSizeTEAD-HA`5’-ATCCATGCTTGTTACCTTCAG-3’``5’-ACTACAAGGACGATGACAAG-3’`460 bpInternal Control`5’-CAGCTCTACATCACCTGCCA-3’``5’-CACTGGGAAGAGACACTCAG-3’`520 bpPCR conditionsDenature: 94**°**C for 30 s Anneal: 56**°**C for 30 s Extend: 72**°**C for 60 s (34 cycles)Dystrophin (WT)`5’-GCGCGAAACTCATCAAATATGCGTGTTAGTGT-3’``5’-GATACGCTGCTTTAATGCCTTTAGTCACTCAGATAGTTGAAGCCATTTTG-3’`134 bpDystrophin\
(*mdx*)`5’-GCGCGAAACTCATCAAATATGCGTGTTAGTGT-3’``5’-CGGCCTGTCACTCAGATAGTTGAAGCCATTTTA-3’`117 bpPCR conditionsDenature: 94**°**C for 20 s Anneal: 60**°**C for 20 s Extend: 72**°**C for 20 s (5 cycles)\
Denature: 94**°**C for 20 s Anneal: 64**°**C for 20 s Extend: 72**°**C for 20 s (23 cycles)utrophin`5’-AGTATGGGGACCTTGAAGCC-3’``5’-CGAGCGTTTATCCATTTGGT-3’`cycloA`5’-ATTTCTTTTGACTTGCGGGC-3’``5’-AGACTTGAAGGGGAATG-3’`actin`5’-CCCTAAGGCCAACCGTGAA-3’``5’-CAGCCTGGATGGCTACGTACA-3’`

Total RNA was extracted and purified from TA muscles using the Direct-zol RNA MiniPrep Kit (ZymoResearch, R2051). Reverse transcription was performed using M-MLV Reverse Transcriptase (Thermo Scientific, 28025013). Real Time PCR was performed using the BioRad CFX96 Real-Time System and primers listed in [Table 1](#tbl1){ref-type="table"}. Data analysis was performed using the CFX manager. Utrophin expression was normalized to both actin and cyclophilin A expression.

Immunofluorescence (IF) {#s4-3}
-----------------------

For IF staining, muscles were isolated, partially imbedded in tragacanth (Sigma 9000-65-1) on a slice of cork, and flash frozen in isopentane (Sigma 78--78-4) cooled by liquid nitrogen. Samples were cryo-sectioned at 10 µm and mounted on Superfrost Plus slides (VWR 48311--703). Following fixation for 10 min (4% PFA/PBS) on ice and PBS wash, antigen retrieval was performed (Dako S1699). Slides were placed in a solution of Sudan black dye (0.1%, Sigma 199664) in ethanol (70%) for 20 min to lessen autofluorescence. Samples were then blocked with 10% normal goat serum diluted in 0.02% triton-100/PBS (PBT). Subsequent primary and secondary antibodes were used at concentrations described ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}) diluted in 2% FBS in 0.02% PBT for one hour to overnight in a humidified chamber. TUNEL labeling was performed immediately following the IF staining protocol using the ApopTag Red In Situ Apoptosis Detection Kit (Millipore, S7165). Coverslips were mounted with a drop of mounting media (Vector Laboratories, H1200) and sealed. All IF images were obtained using Nikon E800 and Zeiss Axioscop microscopes (described below).10.7554/eLife.15461.014Table 2.Primary antibodies used for immunofluorescence. The monoclonal antibodies for Pax7, Myog, Myosin, IIx type myosin, IIa type myosin, non-IIx type myosin, I type myosin, and embryonic myosin, developed by Stefano Schiaffino, C Lucas, A Kawakami, WE Wright, DA Fischman, and HM Blau were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.**DOI:** [http://dx.doi.org/10.7554/eLife.15461.014](10.7554/eLife.15461.014)AntibodiesHostDilutionSourceAnti-Pax7mouse (IgG1)1:4-5DSHB Pax7 (RRID:[AB_528428](https://scicrunch.org/resolver/AB_528428))Anti-Lamininrabbit1:3000Sigma L9393 (RRID:[AB_477163](https://scicrunch.org/resolver/AB_477163))Anti-HArabbit1:1000Invitrogen PA1-985\
(RRID:[AB_559366](https://scicrunch.org/resolver/AB_559366))Anti-HArabbit1:100Sigma H6908\
(RRID:[AB_260070](https://scicrunch.org/resolver/AB_260070))Anti-HAmouse (IgG1)1:100Covance mms-101P (RRID:[AB_2314672](https://scicrunch.org/resolver/AB_2314672))Anti-B1 Integrinrat1:200Abcam AB95623\
(RRID:[AB_10676803](https://scicrunch.org/resolver/AB_10676803))Anti-Mcadherinmouse1:200Santa Cruz SC81471\
(RRID:[AB_2077111](https://scicrunch.org/resolver/AB_2077111))Anti-Calcitonin Receptorrabbit1:250AbD Serotec AHP635\
(RRID:[AB_2068967](https://scicrunch.org/resolver/AB_2068967))Anti-CD34rat1:25BD Biosciences\
553731 (RRID:[AB_395015](https://scicrunch.org/resolver/AB_395015))Anti-Dystrophinmouse1:1000Genetex GTX27164\
(RRID:[AB_386029](https://scicrunch.org/resolver/AB_386029))Anti-Dystrophinrabbit1:100Abcam AB15277\
(RRID:[AB_301813](https://scicrunch.org/resolver/AB_301813))Anti-MyoDrabbit1:50Santa Cruz SC760\
(RRID:[AB_2148870](https://scicrunch.org/resolver/AB_2148870))Anti-MyoDmouse (IgG1)1:200Santa Cruz SC32758\
(RRID:[AB_627978](https://scicrunch.org/resolver/AB_627978))Anti-Myogeninmouse1:20DSHB F5D\
(RRID:[AB_528355](https://scicrunch.org/resolver/AB_528355))Anti-Myogeninmouse (IgG1)1:200Santa Cruz SC12732\
(RRID:[AB_627980](https://scicrunch.org/resolver/AB_627980))Anti-MyHCmouse1:20DSHB MF20 (RRID:[AB_2147781](https://scicrunch.org/resolver/AB_2147781))Anti-eMyHCmouse (IgG1)1:400DSHB F1.652\
(RRID:[AB_528358](https://scicrunch.org/resolver/AB_528358))Anti-myosin (IIX)mouse (IgM)1:2DSHB 6H1\
(RRID:[AB_2314830](https://scicrunch.org/resolver/AB_2314830))Anti-myosin (non-IIX)mouse (IgG1)1:2DSHB BF-35\
(RRID:[AB_2274680](https://scicrunch.org/resolver/AB_2274680))Anti-myosin (IIA)mouse (IgG1)1:2DSHB SC-71\
(RRID:[AB_2147165](https://scicrunch.org/resolver/AB_2147165))Anti-myosin (I)mouse1:2DSHB BA-D5\
(RRID:[AB_2235587](https://scicrunch.org/resolver/AB_2235587))Anti-cleaved caspase 3rabbit1:100Cell Signaling 9664S\
(RRID:[AB_2070042](https://scicrunch.org/resolver/AB_2070042))10.7554/eLife.15461.015Table 3.Secondary antibodies used for immunofluorescence.**DOI:** [http://dx.doi.org/10.7554/eLife.15461.015](10.7554/eLife.15461.015)HostAntigenFluorophoreDilutionSourceGoatRabbit IgGAlexa 4881:1000Invitrogen A11034\
(RRID:[AB_2576217](https://scicrunch.org/resolver/AB_2576217))GoatMouse IgGAlexa 4881:1000Invitrogen A11001\
(RRID:[AB_2534069](https://scicrunch.org/resolver/AB_2534069))GoatMouse IgG1Alexa 4881:100 - 1:1000Invitrogen A21121\
(RRID:[AB_2535764](https://scicrunch.org/resolver/AB_2535764))GoatRabbit IgGAlexa 5681:1000Invitrogen A11011\
(RRID:[AB_2534078](https://scicrunch.org/resolver/AB_2534078))GoatRabbit IgGAlexa 5461:100Invitrogen A11035\
(RRID:[AB_2534093](https://scicrunch.org/resolver/AB_2534093))GoatMouse IgGAlexa 5681:1000Invitrogen A11031\
(RRID:[AB_2534090](https://scicrunch.org/resolver/AB_2534090))GoatRat IgGAlexa 5461:200Invitrogen A11081\
(RRID:[AB_2534125](https://scicrunch.org/resolver/AB_2534125))GoatMouse IgMAlexa 5941:1000Invitrogen A21044\
(RRID:[AB_2535713](https://scicrunch.org/resolver/AB_2535713))

EdU and BrdU cell proliferation assays {#s4-4}
--------------------------------------

EdU was injected at 0.1 mg/20g bodyweight. EdU was detected in muscle sections via Click-iT Kit (Invitrogen C10640). BrdU was detected following IF staining by antigen retrieval (BD biosciences 550803) and ABC amplification (Vector Laboratories PK4000). In cultured cells grown on chamber slides (Sigma C7182) coated in matrigel (Fisher CB-40234), EdU was added to a concentration of 10 µM for 45 min and detected by Click-iT Kit following IF procedures. In experiments of EdU labeled fiber-associated cell clones, EdU (10 µM) was provided throughout the culturing period beginning at t=24 hr.

Histology {#s4-5}
---------

H and E staining has been previously described ([@bib27]). Sections were stained with Sirius Red using protocol and reagents of the Picro-Sirius Red staining kit (American MasterTech KTPSRPT) following fixation in Bouin's solution (Sigma HT01032) for 30 min at 56**°**C. Trichrome stains were performed according to manufacturer's instructions using the Gomori's One-Step Trichrome Kit (Polysciences Inc. 24205). All histology was imaged on the Zeiss Stemi SV11 (for low magnification) and Nikon E800 DIC microscopes (for high magnification) described below.

Evans Blue dye (EBD, Sigma E2129) was administered to mice at a 1% concentration in PBS via intra-peritoneal injection (10 μL/g bodyweight). Mice were sacrificed 20 hr later and the TA and EDL were harvested, flash frozen, then sectioned at 8 μm. Sections were fixed in cold acetone (−20°C) for 10 min, rinsed with PBS, and mounted. The dye's fluorescence was visualized via red light excitation.

Quantifying muscle fiber size {#s4-6}
-----------------------------

Muscle size was determined by weight ([Table 4](#tbl4){ref-type="table"}) and by measurements and quantifications of muscle fibers. Cross-sections (by cryostat sections at 10 µm) of muscles were stained for dystrophin by IF or subjected to H and E stains (for *mdx* muscle samples). Using ImageJ software, fibers were manually outlined and then measured via ImageJ for area and minimum ferret diameter.10.7554/eLife.15461.016Table 4.Weights (mgSD) of respective muscle groups in Wt vs. TEAD1-Tg mice. TEAD1-Tg hind limb muscles are equivalent in weight to Wt. Weight measurements (mg) and standard deviation for TA, EDL, Soleus, and Plantaris muscles from TEAD1-Tg or Wt mice. By t-test no significant difference was found between genotypes (n \> 5 muscles for all measurements).**DOI:** [http://dx.doi.org/10.7554/eLife.15461.016](10.7554/eLife.15461.016)TAEDLSoleusPlantarisWt41.0 ± 5.59.3 ± 1.98.3 ± 1.416.5 ± 2.5TEAD1-Tg38.6 ± 3.49.5 ± 1.59.7 ± 0.914.3 ± 2.7

Myoblast isolation and IF {#s4-7}
-------------------------

Genotyped animals were killed by cervical dislocation and hind limb muscles were removed and minced with scissors. Samples were digested with collagenase and dispase as described previously ([@bib50]). Dissociated muscles were then transferred to 15 mL conical tubes with 10 mL myoblast media (20% fetal bovine serum/5% horse serum in DMEM), spun down in a clinical centrifuge, resuspended in myoblast media, and passed through a 70 µm filter. The remaining cells were twice pre-plated onto uncoated tissue culture dishes for 30 min to remove fibroblasts. The remaining cells were quantified by hemocytometer and placed at equal numbers into wells of chamber slides (Sigma C7182) coated with matrigel (Fisher CB-40234). These cells were differentiated for 2--5 days in media containing 2% horse serum in DMEM. For IF, these cells were fixed with prewarmed 4% PFA/PBS for 10 min, then permeabilized for 15 min in 0.5% PBT and washed with PBS. Primary and secondary antibodies were diluted in goat blocking buffer (blocking powder \[Perkin Elmer P1012\] in normal goat serum \[Genetex GTX73245\]) and applied for one hour to overnight with PBS washes in between primary and secondary antibody applications. After washing, the chamber portion was removed from the slide, and coverslips were mounted using a drop of fluoromount mounting media (Fisher OB100-01) containing DAPI.

Isolation of myofibers {#s4-8}
----------------------

Genotyped animals were killed by cervical dislocation and EDL muscles were placed in a solution of 0.2% collagenase/DMEM for 90 min in a 37°C shaking (80 rpm) water bath. Digested muscles were placed in a pre-warmed solution of DMEM on horse serum coated tissue culture dishes for one hour. The muscles were then titurated with a large bore glass pipette to loosen outer myofibers, which were collected and moved to a new horse serum-coated dish of 10% FBS/DMEM or growth media (20% FBS/ 5% horse serum/ DMEM) via a small bore glass pipette. This continued until sufficient myofibers were obtained. Myofibers were incubated 48 or 72 hr in media (replaced daily). Myofibers were fixed in pre-warmed 4% PFA/PBS for 10 min. The myofibers were then washed three times in PBS and moved to a 1.5 mL microfuge tube. IF of isolated myofibers proceeded as follows: permeabilization (0.5% PBT) occurred for 15 min, myofibers were washed with PBS, then primary and secondary antibodies in goat blocking buffer were applied for one hour to overnight with PBS washes in between primary and secondary antibody applications. Fibers were mounted on Superfrost Plus slides in a drop of mounting media containing DAPI, covered with a coverslip, and sealed with nail polish.

Statistics {#s4-9}
----------

Error bars in histograms represent standard deviation (SD) over either the mean or fold change. Using an excel spreadsheet, all data was subjected to a two-tailed *t* test or chi square test (indicated in figure legend) when appropriate to determine statistical differences. Statistical significance was defined as a p value \<0.05. Sample size was predetermined based on published SC counts, which reveal very low variability, and on preliminary data revealing a highly robust and large change in the number of SCs in TEAD1-Tg mice.

Microscopy {#s4-10}
----------

The Nikon E800 upright epifluorescence microscope uses a 100 watt mercury arc lamp fluorescent source. Images were taken with Hamamatsu Orca-Flash 4.0 LT sCMOS camera under objectives: Plan Fluor 10x (NA 0.30), 20x (NA 0.50), 40x (NA 0.75). The Zeiss Axioskop upright epifluorescence microscope uses an 89North PhotoFluor metal halide fluorescent source. Images were taken with a Zeiss AxioCam monochrome CCD camera under objectives: Plan-Neofluar 10x (NA 0.30), 20x (NA 0.50), Plan-Neofluar 40x (NA 0.75). The Zeiss Stemi SV11 dissecting microscope was used with a Canon EOS Rebel T1i DSLR camera under a 1x objective. The Nikon E800 upright microscope w/ DIC optics was used with a Canon EOS Rebel T3i DSLR camera under objectives: Plan Fluor 4x (NA 0.13), Plan Apo 10x NA 0.45 and Plan Fluor 40x (NA 1.30 Oil).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Muscle fiber signaling scales the myogenic stem cell pool\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Amy Wagers as the Reviewing Editor and Fiona Watt as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this summary with a number of requested changes and additional experiments that are deemed essential for the work to be considered for publication in *eLife*. At this point, we seek your response to these requirements to determine if it is feasible for you to comply within a reasonable length of time.

Summary:

This manuscript from the Lepper & Tsika laboratories evaluates a transgenic animal in which a muscle creatine kinase control region drives expression of TEAD1 in muscle fibers and unexpectedly results in an expansion of the muscle stem cell pool that is established towards the end of embryonic development. With exception of the conclusions regarding satellite cell self-renewal, the authors are careful to avoid overstating or over interpreting their findings, which include several novel and important observations, including: (1) that TEAD1 overexpression in muscle fibers results in a large excess of quiescent satellite cells at birth. This has really interesting implications and supports the notion that the satellite cell niche has room, under the right circumstances, and (2) that having more satellite cells can speed regeneration without causing hypertrophy or prematurely depleting the stem cell pool. Yet, there remain certain aspects of the conclusions that are less well supported by the currently available data. The reviewers engaged in a lively discussion about these issues, and while full agreement could not be achieved, consensus did emerge that certain additional studies are necessary, as detailed below.

Essential revisions:

1\) Issues in interpretation of self-renewal data. All reviewers expressed concerns about the authors\' interpretation of satellite cell self-renewal (subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts", first paragraph). To support their claim, they really need to document loss (and subsequent recovery) of satellite cell number in response to injury, together with BrdU/Edu staining. Otherwise, they cannot exclude the alternative interpretation that the reduction in fold increase (from 6-fold to 3-fold) could reflect a lack of self-renewal (due to incorporation of satellite cells into fibers and failure to regain \"homeostatic\" satellite cell numbers). It is also possible that there is an effect on fusion, which should be investigated through direct experimentation, such as lineage tracing. Several groups have used lineage tracing to mark SCs and demonstrate that there is ongoing SC fusion into myofibers in the adult mouse, which may be occurring in the absence of SC division. One would predict that an increase in SCs would cause an increase in SC fusion. Lineage tracing of TEAD-1 tg mice with an appropriate lineage marker is well within the expertise of the authors and could aid in further delineating the observed phenotypes. Thus, extensive additional data are needed to support the self-renewal claims, and the authors may instead wish to edit the text to remove that claim from the Results section.

2\) Related to the above, in the Pax7/MyoD data in [Figure 8](#fig8){ref-type="fig"}, the authors cannot claim that Pax7^+^ only cells reflect a self-renewing fates without also showing that these the cells incorporate BrdU. They could simply be non-dividing, rather than self-renewing.

3\) Issues in interpretation of *mdx* data. The amelioration of the dystrophic phenotype that the authors see is interesting and important, but it is possible that it is completely unrelated to any effect on satellite cells. TEAD overexpression could independently impact muscle fibers, e.g., by increasing their stability through upregulation of compensatory pathways (e.g. utrophin) or alteration of splicing, resulting in an increased frequency of revertant fibers. These considerations are presented in a more balanced manner in the Discussion than in the Results section, which should be rectified. It would be best if this issue were addressed experimentally, perhaps by ablating satellite cells in the model to determine whether this blunts the improvement seen with MCK-TEAD. Further data on addressing fibrosis, membrane leakage, regeneration or muscle function in *mdx*/TEAD-1 tg mice or in wild type mice would also be useful in supporting the authors\' conclusions.

4\) Issues related to the non-autonomy of the observed effect. Additional data in support of the cell non-autonomous mechanism is needed. It is not clear from the prior Tsika publication whether TEAD1 is expressed in satellite cells, cycling myoblasts, myocytes, or myotubes. This should be more carefully addressed experimentally to clarify expression of endogenous and exogenous TEAD at these different myogenic stages. HA staining on quiescent/homeostatic tissue, as they have done, is not sufficient. A time-course analysis of HA & TEAD1 before and after SC activation (in vivo or in vitro activation) is warranted. Presuming that HA-TEAD1 expression is lacking in satellite cells, the authors should then perform transplantation studies to confirm the non-autonomous effects of MCK-TEAD1 transgene.

5\) Issues in the exclusive use of transgenic overexpression. One reviewer in particular expressed deep concerns regarding the potential for non-physiological outcomes as a result of excessive overexpression of a transcription factor. This issue should be explicitly discussed in the manuscript, and ideally, would be addressed most effectively by the inclusion of complementary loss-of-function studies for at least some of the outcomes evaluated (perhaps using AAV delivery of inhibitory constructs).

6\) Further fiber type analysis, at the level of quantifying% fibers of each type, is needed in the HA-TEAD1 mice.

7\) Apoptotic rates should be reported in the in vivo and in vitro systems. An alternative hypothesis is that the cells accumulate because they are protected from cell death, and this possibility is not addressed currently.

8\) A deeper single fiber analysis is needed to support conclusions about SC clone size (BrdU, transparency with SC numbers, assess viability, etc.). While the authors argue that the isolated myofiber cultures ([Figure 8](#fig8){ref-type="fig"}) show increased clone sizes of SCs on TEAD-1 tg vs. wild type mice, the numbers of cells are not provided. How many SCs are on TEAD-1 myofibers at the experiment initiation and how many SCs at the conclusion? It is possible that the increase in clone size is due to segregation of TEAD-1 SCs into fewer and larger clones.

9\) Finally, it is important to discuss the current data in light of the mechanisms and signaling pathways identified as perturbed in the prior work. For example, Wnt signaling is nearly eliminated as well as NFATc1 and NFATc3. Increased wnt signaling induces hypertrophy and NFAT signaling is involved in myocyte fusion, thus, TEAD-1 over expression in myofibers may inhibit cell fusion and thus, the balance of excess SCs and inhibition of hypertrophy and cell fusion might balance each other and prevent hypertrophy.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Muscle fiber signaling scales the myogenic stem cell pool\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Fiona Watt as the Senior Editor and two reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been significantly improved but there are a few remaining issues that need to be addressed through edits to the text before acceptance. These are outlined below, accompanied by the rationale for each requested change:

1\) Self-renewal data. The authors make an interesting point regarding the data of Webster et al., which indeed use intravital imaging to argue that satellite cell number is not diminished after cardiotoxin injury (although this conclusion contrasts with other reports (see Gayraud-Morel et al. 2009 and Hardy et al. 2016), and there are important limitations to their methodology, most importantly the limited muscle area that could be analyzed (only about 5-7 fiber diameters) due to limitations of microscope imaging depth (\<200 μm), which could lead to sampling error if muscle damage is uneven, as is common with cardiotoxin injury). Regardless, given the authors\' stance on satellite cell loss after injury, they may wish to edit the sentence in the subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts", which indicates that satellite cells must \"replenish themselves during each regeneration bout\", as this seems to suggest that satellite cell numbers drop. Perhaps they really mean \"to maintain their numbers as cells are recruited for fusion into myofibers\"?

Regarding the EdU incorporation data the authors have added in support of their claim of TEAD1-Tg self-renewal, these data clearly show that TEAD1-Tg cells proliferate as well as WT, but [Figure 7Q-R](#fig7){ref-type="fig"} shows that average SC number per area increases with injury in WT and decreases in TEAD1-Tg, which suggests that TEAD1-Tg cells are maintained less well after injury, as compared to WT, although the starting number of these cells is higher. The authors consider this issue explicitly now in the Discussion, but they should also add a comment to the Results section noting that while Edu incorporation studies indicate that TEAD1-Tg satellite cells are capable of self-renewal, the loss of TEAD1-Tg cells (from uninjured to 3x injured) could reflect a diminished self-renewal capacity. The current text does not provide sufficient clarity for this important point.

2\) The authors have provided an extensive discussion in their response letter delineating the reasons that they have not pursued loss-of-function studies (LOF). It is fair to say that for this family of factors, LOF studies are challenging (though maybe one should not go so far as to conclude that they are \"futile\"); however, the authors should still include discussion of this issue in their paper, citing their conceptual focus on \"the plasticity of the muscle stem cell niche\" and the need for further studies to evaluate loss of function models in order to assess the requirement for TEAD1 in normal regulation of SC number, in order to avoid misinterpretation or overinterpretation of their results by others.

3\) The title should be changed; the current title is vague and furthermore implies an analysis of normal regulation of SC number (which the authors have specifically stated they do not wish to claim). A better title would be: TEAD1 overexpression in mouse muscle fibers drives satellite cell hyperplasia and counters pathological effects of dystrophin deficiency.

4\) In light of the new data on utrophin expression in TEAD-expressing *mdx* muscle and since the authors do not know if the amelioration of pathology in this model is related to SC hyperplasia, the last sentence of the Abstract should be edited to include: \"... targets for enhancing muscle regeneration and ameliorating muscle pathology.\"

5\) Introduction: \"Remarkably, in the *mdx* mouse model \[...\] pathology is significantly ameliorated by TEAD1-overexpression.\" Because this sentence follows the discussion of supranumeral SCs in TEAD1-Tg mice, it implies that SC hyperplasia underlies the improved pathology, but the authors now provide an alternative model. The upregulation of utrophin in TEAD1-Tg *mdx* muscle should be noted here also to avoid confusion. Similarly, a following sentence: \"This work implicates a role for \[...\]\" should include comment that TEAD1-induced myofiber-derived signaling can scale the SC pool AND alter myofiber stability in the context of dystrophic disease.

6\) The authors have added new and rather dramatic results of fiber type analysis, which indicate a complete absence of IIx fibers in TEAD1-Tg muscle. The authors need to specify which muscle group was analyzed in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and indicate whether these results were the same across the 4 muscle groups they chose for further analysis ([Figure 1](#fig1){ref-type="fig"}). Also, as IIx fibers account for 1/2 of all fibers in normal mice, the authors must consider the possibility (and discuss it in the manuscript) that this fiber type shift contributes to SC hyperplasia and DMD protection. Currently, this is in the Results, but not in the Discussion. Prior work (see e.g. Collins et al. 2005) clearly indicates that satellite cell content is different in muscle with different fiber type composition (e.g. Collins shows and \~4fold increase in satellite cell per myofiber in the soleus as compared to the EDL). This work should be cited and discussed.
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Author response

Essential revisions:

*1) Issues in interpretation of self-renewal data. All reviewers expressed concerns about the authors\' interpretation of satellite cell self-renewal (subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts", first paragraph). To support their claim, they really need to document loss (and subsequent recovery) of satellite cell number in response to injury, together with BrdU/Edu staining. Otherwise, they cannot exclude the alternative interpretation that the reduction in fold increase (from 6-fold to 3-fold) could reflect a lack of self-renewal (due to incorporation of satellite cells into fibers and failure to regain \"homeostatic\" satellite cell numbers). It is also possible that there is an effect on fusion, which should be investigated through direct experimentation, such as lineage tracing. Several groups have used lineage tracing to mark SCs and demonstrate that there is ongoing SC fusion into myofibers in the adult mouse, which may be occurring in the absence of SC division. One would predict that an increase in SCs would cause an increase in SC fusion. Lineage tracing of TEAD-1 tg mice with an appropriate lineage marker is well within the expertise of the authors and could aid in further delineating the observed phenotypes. Thus, extensive additional data are needed to support the self-renewal claims, and the authors may instead wish to edit the text to remove that claim from the Results section.*

We have performed additional regeneration experiments including SC proliferation assays via EdU to address the referees' concerns about our interpretation of SC self-renewal during regeneration. We disagree with the Referee's opinion that an initial loss of SCs in injury-induced regeneration with subsequent SC recovery needs to be documented to draw a conclusion about SC self-renewal. Indeed, intra-vital imaging of lineage-labeled SCs does not reveal any loss of SCs in response to injury (Webster et al., Cell Stem Cell, 2015). Thus, it appears such an assay would be unreliable to assessing SC self-renewal. Our new regeneration experiments including EdU show that a large percentage of SCs have proliferated prior to replenishing the SC pool in TEAD1-Tg muscle regenerates, which demonstrates their ability to self-renew ([Figure 7J-L](#fig7){ref-type="fig"}; subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts". 12-20). Additional single myofiber culture experiments revealed that 100% of Pax7^+^ cells have proliferated on TEAD1-Tg myofibers ([Figure 9N-P](#fig9){ref-type="fig"}; subsection "Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle", second paragraph), further substantiating our claim of self-renewal by SCs of TEAD1-Tg muscle. We believe together, these new data provide extensive and sufficient evidence to solidify our conclusion about the self-renewal ability of SCs of TEAD1-Tg mice.

We respectfully disagree with the referees' opinion that lineage-tracing of SCs would help to "further delineating the observed phenotypes." Our observations center around the surprising ability of the skeletal muscle niche to support extra-numeral SCs and the effect of such super-numeral SCs on regeneration. We refrain from drawing any conclusions about the normal homeostatic maintenance of the SC hyperplasia. While we agree that future studies of the TEAD1-Tg mouse model during long-term tissue homeostasis and/or aging are much desired, they are outside the scope and focus of our present study. However, we have expanded on our discussion regarding the reduction in the fold-increase of SCs upon regeneration. Along this line, we find the Referee's remark regarding a potential lack of self-renewal to be highly insightful. Our new data argues against a complete lack of self-renewal. However, we concede that a diminished self-renewal capacity could account for the reduction in the fold-increase of SCs after injury. The Referee's comment forced us to think more deeply about the change in the magnitude of the SC hyperplasia. In contrast to the early post-natal SC niche that drives the establishment of super-numeral SCs in TEAD1-Tg mice, the adult niche is destroyed by injury. The transient loss of the TEAD1-expressing cell, i.e. the muscle fiber, likely diminishes the ability of the tissue to promote SC hyperplasia to the same degree as the early post-natal myofiber. We have expanded our Discussion section accordingly to account for these two possible scenarios (subsection "Reduced SC hyperplasia of regenerated muscle").

*2) Related to the above, in the Pax7/MyoD data in [Figure 8](#fig8){ref-type="fig"}, the authors cannot claim that* Pax7^+^*only cells reflect a self-renewing fates without also showing that these the cells incorporate BrdU. They could simply be non-dividing, rather than self-renewing.*

We observe clonal expansion of SCs on TEAD1-Tg myofibers with the presence of Pax7^+^ only cells within the SC colonies. These data strongly suggest that these SCs do divide and self-renew. We made the conclusion about the SC self-renewal based on the fraction of Pax7^+^ cells per prior publications from several different laboratories. To directly demonstrate this, we have performed additional single myofiber explant experiments including SC proliferation analysis via EdU ([Figure 9N-P](#fig9){ref-type="fig"};subsection "Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle", second paragraph). The results demonstrate that Pax7^+^ cells have indeed divided reflecting the self-renewing fate and further supporting our claim about SC self-renewal in vivo (see response to major point 1). Moreover, we found significantly increased proliferation by Pax7-expressing SCs of TEAD1-Tg compared to wild type fibers. These data corroborate the increased proliferation rates by SCs in vivo ([Figure 3F-G](#fig3){ref-type="fig"}) and provide mechanistic insight into the acquisition of extra-numeral SCs, i.e. via hyper-proliferation.

*3) Issues in interpretation of mdx data. The amelioration of the dystrophic phenotype that the authors see is interesting and important, but it is possible that it is completely unrelated to any effect on satellite cells. TEAD overexpression could independently impact muscle fibers, e.g., by increasing their stability through upregulation of compensatory pathways (e.g. utrophin) or alteration of splicing, resulting in an increased frequency of revertant fibers. These considerations are presented in a more balanced manner in the Discussion than in the Results section, which should be rectified. It would be best if this issue were addressed experimentally, perhaps by ablating satellite cells in the model to determine whether this blunts the improvement seen with MCK-TEAD. Further data on addressing fibrosis, membrane leakage, regeneration or muscle function in mdx/TEAD-1 tg mice or in wild type mice would also be useful in supporting the authors\' conclusions.*

We have performed several new experiments to strengthen our conclusions about the amelioration of the dystrophic pathology in *mdx;* TEAD1-Tg mice. We have assayed for fibrosis via Trichrome staining and membrane leakage via Evans Blue dye uptake ([Figure 8F-K](#fig8){ref-type="fig"};subsection "Dystrophic pathology is ameliorated in *mdx*; TEAD1-Tg skeletal muscle", first paragraph). The results provide further evidence for a dramatically improved dystrophic pathology in these mice. To gain mechanistic insight into the amelioration of the dystrophy, we assayed for revertant fibers and changes in utrophin expression per the Referee's insightful suggestions. While we do not detect any increased rates of myofiber reversion (subsection "Dystrophic pathology is ameliorated in *mdx*; TEAD1-Tg skeletal muscle", last paragraph), we discovered significant up-regulation of *utrophin* transcripts in *mdx;* TEAD1-Tg muscle ([Figure 8O](#fig8){ref-type="fig"}; in the aforementioned paragraph). These new data suggest that stabilization of the sarcolemma via utrophin up-regulation contributes to amelioration of the dystrophic muscle pathology of *mdx;* TEAD1-Tg mice. Please note that to accommodate extra data points our previous [Figure 7](#fig7){ref-type="fig"} was split into two figures, i.e. [Figure 7](#fig7){ref-type="fig"} and [Figure 8](#fig8){ref-type="fig"}.

We appreciate the referee's opinion that our observations are "interesting and important" and agree that addressing any potential contribution from the increased SC pool to ameliorating the dystrophic phenotype experimentally is much desired. But we believe the identification of the origin of the amelioration of the dystrophy, e.g. increased SCs or increase in slow-twitch muscle program, to be deserving of an entirely separate study. To this end, prior publications reporting amelioration of dystrophy via shifting fast-twitch to slow-twitch myofibers did not investigate any potential contributions from SCs. The Referee suggested ablating SCs in our model to determine whether this blunts the improvement. We believe this to be a good experiment though it is unclear if conclusive answers can be gained from such studies. As far as we know, SC ablation in the *mdx* mouse model has not been done yet. Thus, it is not clear when the ablation can be performed and how long mice would survive. In fact, our Pax7-CreERT2 allele cannot be used for such experiments as even non-dystrophic mice die within a week after SC ablation (Development, 2011). Use of different Pax7-CreERT2 alleles could complicate the analysis, as SC ablation is incomplete. Furthermore, SC ablation in the *mdx;* TEAD1-Tg mouse would likely need to be performed at or prior to the initial onset of the SC hyperplasia 2 weeks after birth since the observed muscle improvement is a cumulative effect of myofiber-specific TEAD1 expression beginning much before the onset of the pathology in *mdx* mice. SC ablation during the early period after birth when muscle is still growing by fusion from SCs has not been attempted but may likely impact the normal growth of the muscle tissue, therefore rendering this approach impractical to obtain any conclusive data. We do agree that a separate study regarding the contribution, if any, of SCs to the improvement of the dystrophic phenotype should be done. Ideally, such a study should include all prior models based on a shift from fast- to slow-twitch muscle program and yielding amelioration of the dystrophic phenotype. We expanded our discussion about the amelioration of the dystrophic pathology in *mdx;* TEAD1-Tg mice to account for our finding of compensatory utrophin up-regulation and unknown contribution (if any) from extra-numeral SCs (subsection "Ameliorated dystrophy in *mdx*; TEAD1-Tg mice").

*4) Issues related to the non-autonomy of the observed effect. Additional data in support of the cell non-autonomous mechanism is needed. It is not clear from the prior Tsika publication whether TEAD1 is expressed in satellite cells, cycling myoblasts, myocytes, or myotubes. This should be more carefully addressed experimentally to clarify expression of endogenous and exogenous TEAD at these different myogenic stages. HA staining on quiescent/homeostatic tissue, as they have done, is not sufficient. A time-course analysis of HA & TEAD1 before and after SC activation (in vivo or in vitro activation) is warranted. Presuming that HA-TEAD1 expression is lacking in satellite cells, the authors should then perform transplantation studies to confirm the non-autonomous effects of MCK-TEAD1 transgene.*

To address the referee's concern regarding the non-autonomy of the SC hyperplasia, we now provide additional in vitro TEAD1 transgene expression data ([Figure 9C](#fig9){ref-type="fig"};subsection "Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle", first paragraph). These new data confirm our in vivo expression analysis, which demonstrated exclusion of the HA-tagged TEAD1 from Pax7^+^ SCs. We did not detect any HA signal in Pax7-expressing reserve cells. Instead, all HA signal was exclusively contained within the domain of post-mitotic differentiated myocytes (Myogenin^+^). Together with the EdU proliferation data revealing increased proliferation of SCs from TEAD1-Tg mice only when still associated with the myofiber ([Figure 9K-P](#fig9){ref-type="fig"}), these new data significantly substantiate our claim about the non-cell-autonomous induction of the SC increase.

Regarding the proposed transplantation studies, we believe such experiments would not yield any reliable data to demonstrate the non-cell-autonomous effects of the MCK-TEAD1 transgene. For this experiment to work, highly robust and consistently repeatable SC engraftment would need to be achieved to allow for the necessary precise quantifications of wild type SCs in TEAD1 transgenic skeletal muscle. In our hands, variability of such SC engraftment is too large to allow for this assay to work reliably. Moreover, such SC engraftments would need to be performed into early postnatal muscle at the onset of the SC hyperplasia (around 2 weeks after birth). Preliminary attempts to graft SCs into 2-week-old mice proved unsuccessful resulting in a very high rate of cannibalism. Likely for this reason, SC transplantation into early postnatal muscle has not been a standard assay in the field.

*5) Issues in the exclusive use of transgenic overexpression. One reviewer in particular expressed deep concerns regarding the potential for non-physiological outcomes as a result of excessive overexpression of a transcription factor. This issue should be explicitly discussed in the manuscript, and ideally, would be addressed most effectively by the inclusion of complementary loss-of-function studies for at least some of the outcomes evaluated (perhaps using AAV delivery of inhibitory constructs).*

We acknowledge the referee's concerns regarding the potential for non-physiological outcomes as a result of overexpression of the TEAD1 transcription factor. While we observe a rather moderate TEAD1 overexpression levels (e.g. 3.3-fold in the gastrocnemius and 2.4-fold in the soleus), this could still result in transcriptional outcomes normally not affected by endogenous TEAD transcription factors. As such, we are careful to not draw conclusions about the role of TEAD1 in skeletal muscle fibers but instead conceptually highlight the surprising plasticity of the muscle stem cell niche to harbor a large excess of SCs concomitant with sped-up muscle regeneration. As such, we would like to argue that whether TEAD1 overexpression could affect non-physiological pathways is of lesser concern for our current study. We agree that loss-of-function studies to elucidate the role of Tead transcription factors in skeletal muscle would be highly informative. At present, such studies are hindered by the co-expression of all four functionally equivalent Tead (TEAD1,2,3,4) transcription factors by skeletal muscle tissue (Tsika et al., 2008 and references within). Furthermore, germline null mutation of TEADs 1 and 4 result in embryonic lethality, and of the small percentage of TEAD2 mice that survive, they carry defects in neural tube closure. Compound null mutations of TEAD1/TEAD2 leads to embryonic lethality. TEAD3 KO mice have not been studied as of yet. Thus, the resulting embryonic lethality of TEAD null mice preclude their use in our ongoing studies requiring the generation of conditional alleles for all four Tead genes.

The referee suggested the use of TEAD inhibitory constructs by using AAV delivery. All four TEAD-transcription factors bind to highly conserved cis-acting regulatory elements (MCAT, A/T-rich) and display overlapping functional roles (Meng et al., Genes & Devlop, 2016). To overcome issues of functional redundancy between the various TEAD family members, dominant negative TEAD constructs (i.e. dnTEAD2) that lack the TEA-DNA binding domain have been generated and tested in vitro and in vivo (e. g., Cao et al., Genes & Dev., 2008). While these constructs are successful in reducing/eliminating TEAD target gene expression, complications arise in data interpretation as the remaining C-terminal portion of TEAD is expressed and harbors the necessary interaction site for its coactivators: YAP, TAZ, and Vgll(**1-4**) ((Meng et al., Genes & Devlop, 2016). TEADs have very weak activation domains and require interactions with potent co-activators to confer robust gene expression (Meng et al., Genes & Development, 2016). The resulting data will very likely reflect altered TEAD, YAP, TAZ, and Vgll(1-4) gene programs. Ultimately, conditional KO mice for TEAD1-4 would have to be generated. We do not know if transgenic TEAD1 recruits any of its co-activators for affecting the myofiber genetic program resulting in increased SCs. Therefore, it is not clear if this approach could effectively abrogate transcriptional events stemming from TEAD1 activity. Moreover, the role of YAP in skeletal muscle fibers is controversial. While two studies suggest YAP positively regulates myofiber size (Watt et al., Nature Commun., 2015 & Goodman et al., FEBS Letter, 2015), one study implicates YAP in muscle atrophy and myopathy (Judson et al., Plos One, 2013). As such, the use of dominant negative TEAD constructs (involving blocking of YAP) appears impractical to gaining conclusive insight into the functional role of the Tead transcription factors in skeletal muscle fibers. Using gene knock-down approach via shRNA also appears impractical considering that a total of four Tead genes would have to be sufficiently knocked-down by inhibitory constructs. Moreover, virtually any cell in skeletal muscle tissue could be transduced by AAV precluding specific delivery to skeletal muscle fibers. The utility of this approach is further compromised by the rather long *lag time*after infection for maximal gene*expression*seen for AAV in virtually all tissues. This presents itself as a potentially significant problem since delivery of shRNA (or DN constructs above) would have to be performed during the early post-natal period when the quiescent SC pool is first established. With an unknown lag time of transgene expression, one cannot know when to deliver the virus. Thus, this approach is also likely futile to assessing Tead function in postnatal skeletal muscle.

*6) Further fiber type analysis, at the level of quantifying% fibers of each type, is needed in the HA-TEAD1 mice.*

We now provide fiber type analysis of TEAD1-Tg skeletal muscle via immuno-fluorescence stainings using antibodies against fiber-type specific myosins ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; subsection "TEAD1-Tg mice have normal skeletal muscle size and number, but have SC hyperplasia", first paragraph). IIX myosin^+^ myofibers are lost and at least in part replaced by IIA myosin^+^ fibers. These results confirm the previously documented fast- to slow-twitch myofiber transition in TEAD1-Tg mice (Tsika et al., J Biol Chem, 2008).

*7) Apoptotic rates should be reported in the in vivo and in vitro systems. An alternative hypothesis is that the cells accumulate because they are protected from cell death, and this possibility is not addressed currently.*

We have performed additional experiments to assay for apoptotic rates by SCs of TEAD1-Tg muscle both in vivo and in vitro ([Figure 3H-J](#fig3){ref-type="fig"};subsection "SC hyperplasia is established during early postnatal development"). We did not find any differences in apoptotic rates between wild type and TEAD1-Tg samples suggesting SC protection from apoptosis is not a mechanism by which extra-numeral SCs are acquired by TEAD1-Tg muscle.

*8) A deeper single fiber analysis is needed to support conclusions about SC clone size (BrdU, transparency with SC numbers, assess viability, etc.). While the authors argue that the isolated myofiber cultures ([Figure 8](#fig8){ref-type="fig"}) show increased clone sizes of SCs on TEAD-1 tg vs. wild type mice, the numbers of cells are not provided. How many SCs are on TEAD-1 myofibers at the experiment initiation and how many SCs at the conclusion? It is possible that the increase in clone size is due to segregation of TEAD-1 SCs into fewer and larger clones.*

We have performed additional single myofiber explant experiments and quantified SCs at t=0 and SC colonies at t=72 ([Figure 9N-R](#fig9){ref-type="fig"};subsection "Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle", second paragraph). Importantly, we did not find any evidence for fusion of SCs into fewer and larger clones to account for the increased clone sizes. Indeed, we found that clone fracturing occurs more frequently than clone fusion and at similar rates between wild type and TEAD1-Tg samples. Yet, clone size was significantly increased on TEAD1-Tg myofibers. We truly appreciate this comment by the Referee as these detailed in-depth analyses of clone size increases coupled with the EdU proliferation data (see response to major point 2) significantly strengthen our conclusions regarding TEAD1-Tg myofiber affecting SC proliferation, which provides an explanation for the hyperplasia phenotype (discussed in the last paragraph of the subsection "Non-cell autonomous induction of SC hyperplasia in TEAD1-Tg muscle").

*9) Finally, it is important to discuss the current data in light of the mechanisms and signaling pathways identified as perturbed in the prior work. For example, Wnt signaling is nearly eliminated as well as NFATc1 and NFATc3. Increased wnt signaling induces hypertrophy and NFAT signaling is involved in myocyte fusion, thus, TEAD-1 over expression in myofibers may inhibit cell fusion and thus, the balance of excess SCs and inhibition of hypertrophy and cell fusion might balance each other and prevent hypertrophy.*

We appreciate the reference to our prior work regarding possible mechanisms and signaling pathways affecting the SC hyperplasia. We have added a discussion of our previous findings of diminished NFAT and Wnt signaling in TEAD1-Tg muscle with regard to the lack of any muscle tissue size alterations (subsection "SC hyperplasia without muscle hypertrophy").

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*1) Self-renewal data. The authors make an interesting point regarding the data of Webster et al., which indeed use intravital imaging to argue that satellite cell number is not diminished after cardiotoxin injury (although this conclusion contrasts with other reports (see Gayraud-Morel et al. 2009 and Hardy et al. 2016), and there are important limitations to their methodology, most importantly the limited muscle area that could be analyzed (only about 5-7 fiber diameters) due to limitations of microscope imaging depth (\<200 μm), which could lead to sampling error if muscle damage is uneven, as is common with cardiotoxin injury). Regardless, given the authors\' stance on satellite cell loss after injury, they may wish to edit the sentence in the subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts", which indicates that satellite cells must \"replenish themselves during each regeneration bout\", as this seems to suggest that satellite cell numbers drop. Perhaps they really mean \"to maintain their numbers as cells are recruited for fusion into myofibers\"?*

We have edited the sentence according to the referee's suggestion (subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts").

*Regarding the EdU incorporation data the authors have added in support of their claim of TEAD1-Tg self-renewal, these data clearly show that TEAD1-Tg cells proliferate as well as WT, but [Figure 7Q-R](#fig7){ref-type="fig"} shows that average SC number per area increases with injury in WT and decreases in TEAD1-Tg, which suggests that TEAD1-Tg cells are maintained less well after injury, as compared to WT, although the starting number of these cells is higher. The authors consider this issue explicitly now in the Discussion, but they should also add a comment to the Results section noting that while Edu incorporation studies indicate that TEAD1-Tg satellite cells are capable of self-renewal, the loss of TEAD1-Tg cells (from uninjured to 3x injured) could reflect a diminished self-renewal capacity. The current text does not provide sufficient clarity for this important point.*

We now include a sentence discussing the possibility of reduced self-renewal capacity by SCs of TEAD1-Tg mice in the Results section,(subsection "Super-numeral SCs of TEAD1-Tg muscle retain full regenerative capacity over repeated injury-induced regeneration bouts").

*2) The authors have provided an extensive discussion in their response letter delineating the reasons that they have not pursued loss-of-function studies (LOF). It is fair to say that for this family of factors, LOF studies are challenging (though maybe one should not go so far as to conclude that they are \"futile\"); however, the authors should still include discussion of this issue in their paper, citing their conceptual focus on \"the plasticity of the muscle stem cell niche\" and the need for further studies to evaluate loss of function models in order to assess the requirement for TEAD1 in normal regulation of SC number, in order to avoid misinterpretation or overinterpretation of their results by others.*

We agree with the Referee that future studies are warranted to determine if the Tead family of transcription factors plays a functional role in the regulation of SC number and have included a discussion about this in the revised manuscript (subsection "TEAD1-Tg mice: A novel mouse model for SC hyperplasia", last paragraph).

*3) The title should be changed; the current title is vague and furthermore implies an analysis of normal regulation of SC number (which the authors have specifically stated they do not wish to claim). A better title would be: TEAD1 overexpression in mouse muscle fibers drives satellite cell hyperplasia and counters pathological effects of dystrophin deficiency.*

We sincerely thank the referee or editor for suggesting a title that we feel is highly accurate for our manuscript. It is clear that a lot of thought went into crafting this title. The character count of the suggested title is 120 words without spaces, but 136 with spaces and it appears that the character limit placed by *eLife* is 120 words including spaces. We have spent a lot of efforts on our side trying to reduce the title to be within this limitation. We tried our best to not lose any information from the suggested title. We have changed our manuscript title to: "Myofiber-specific TEAD1 overexpression drives satellite cell hyperplasia and improves pathology of dystrophin deficiency". However, we would like to note that we actually prefer the referee's/editor's suggested title and would be happy if it was used instead -- if *eLife* allowed it.

*4) In light of the new data on utrophin expression in TEAD-expressing mdx muscle and since the authors do not know if the amelioration of pathology in this model is related to SC hyperplasia, the last sentence of the Abstract should be edited to include: \"... targets for enhancing muscle regeneration and ameliorating muscle pathology.\"*

We thank the referee for enhancing the impact of our manuscript's Abstract by suggesting to expand the Abstract to reflect our new insight into the amelioration of the dystrophic pathology by the TEAD1 transgene. We have edited our Abstract accordingly. Please note that to keep within less than 150 words, we have eliminated two words ('quiescent' and 'adult').

*5) Introduction: \"Remarkably, in the mdx mouse model...pathology is significantly ameliorated by TEAD1-overexpression.\" Because this sentence follows the discussion of supranumeral SCs in TEAD1-Tg mice, it implies that SC hyperplasia underlies the improved pathology, but the authors now provide an alternative model. The upregulation of utrophin in TEAD1-Tg mdx muscle should be noted here also to avoid confusion. Similarly, a following sentence: \"This work implicates a role for...\" should include comment that TEAD1-induced myofiber-derived signaling can scale the SC pool AND alter myofiber stability in the context of dystrophic disease.*

We agree with the referee that the previous ordering of our summary at the end of our Introduction may have been confusing as to the origin of the amelioration of the dystrophic pathology. For enhanced clarity, have edited the text according to the referee's suggestions (Introduction, last paragraph).

*6) The authors have added new and rather dramatic results of fiber type analysis, which indicate a complete absence of IIx fibers in TEAD1-Tg muscle. The authors need to specify which muscle group was analyzed in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and indicate whether these results were the same across the 4 muscle groups they chose for further analysis ([Figure 1](#fig1){ref-type="fig"}). Also, as IIx fibers account for 1/2 of all fibers in normal mice, the authors must consider the possibility (and discuss it in the manuscript) that this fiber type shift contributes to SC hyperplasia and DMD protection. Currently, this is in the Results, but not in the Discussion. Prior work (see e.g. Collins et al. 2005) clearly indicates that satellite cell content is different in muscle with different fiber type composition (e.g. Collins shows and \~4fold increase in satellite cell per myofiber in the soleus as compared to the EDL). This work should be cited and discussed.*

We thank the referee for bringing to our attention that we had not sufficiently discussed potential contributions from the fast- to slow-twitch myofiber transition to the SC hyperplasia in our Discussion section. While the results of an absence of IIX fibers by immuno-fluorescence staining on sections is dramatic, they did not come as a surprise to us, as our previous work had already demonstrated this loss by high resolution glycerol gel electrophoresis (Tsika, 2008). If the SC hyperplasia was a 'passive bystander effect' of the fast- to slow-twitch myofiber transition, then little to no change in SC numbers should be observed in a pre-dominantly slow-twitch muscle devoid of type IIX fibers such as the soleus. The opposite, however, is the case. In TEAD1-Tg mice, the soleus features the largest increase in SCs of all muscles analyzed. These data strongly argue against the SC hyperplasia to exclusively originate from the fast- to slow-twitch myofiber transition, i.e. loss of type IIX fibers. We welcome the opportunity to make this point clearer and thank the referee for bringing work from Collins et al. to our attention, which we now also cite (subsection "TEAD1-Tg mice: A novel mouse model for SC hyperplasia", first paragraph). We have applied the fiber type analysis to the TA muscle, which normally contains both fast- and slow-twitch myofibers. This is now indicated in the figure legend of [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

[^1]: These authors contributed equally to this work.
